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Abstract 
 
Severe mental disorders including schizophrenia often segregate within the same 
families. Twin and family studies suggest that this co-occurrence is largely genetic, 
which implies that the different mental disorders have a shared genetic background. 
Some symptomatic features, such as cognitive impairment also manifest to a 
variable degree in the majority of severe mental disorders. Cognitive impairment 
occurs already before the onset of the disease and healthy family members of 
patients perform worse in cognitive tests than do the general population, which 
suggests that the cognitive impairment is indicative of genetic loading of the disease. 
Furthermore, the cognitive impairment persists throughout the disease and is 
associated with poorer outcome. This led us to hypothesize that the genetic 
architecture of schizophrenia is more similar to developmental disorders than had 
been considered earlier. Specifically, we hypothesized that rare high impact genetic 
variants play a role in the genetic risk for schizophrenia. Rare recurrent large-scale 
structural variation has long known to cause developmental syndromes, such as 
Prader-Willi syndrome or Velocardiofacial syndrome. In this study we investigated 
the role of large-scale chromosomal copy number variants in the genetic background 
of schizophrenia and other traits hypothesized to reflect abnormal neuronal 
development. 
 
In this study four chromosomal deletions on 1q21, 15q11.2, 15q13.3 and 22q11.2 
were identified to be associated with schizophrenia. Three of the deletions occurred 
recurrently, whereas the deletion on 22q11.22 was a founder mutation enriched 
especially in the North-East region of Finland. On a population level, carriers of 
large deletions were found to have more intellectual disability or sub-normality 
(IQ<85) than non-carriers. Also milder learning difficulties as measured by repeated 
grades in school were more common among carriers of large deletions. The four 
deletions specifically identified as associating with schizophrenia are linked to 
variable phenotypes with the strongest effect manifesting in intellectual disabilities. 
The regional enrichment of the deletion on 22q11.22 also enabled the assessment of 
recessive effects related to the deletion. Four individuals, all presenting with a 
neurodevelopmental phenotype and/or schizophrenia, were identified as 
homozygous for the deletion. This deletion overlaps one gene encoding for 
topoisomerase 3 beta (TOP3β) that forms a protein complex with FMRP, the fragile 
X mental retardation protein, via tudor domain containing 3 (TDRD3) protein.  
 
The results of this study imply that rare high risk variants are present in a sub set of 
schizophrenia patients and that these variants are shared with developmental 
disorders. The study also demonstrates that special populations such as population 
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isolates can provide useful study designs in identifying rare genetic risk variants, 
especially with recessive effects for complex traits. 
 
Keywords: schizophrenia, cognitive functions, copy number variations (CNVs), 
Genome-wide association studies (GWAS) 
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Tiivistelmä 
 
Monet vakavat mielenterveydenhäiriöt, kuten skitsofrenia, kasaantuvat usein 
samoihin perheisiin. Kaksos- ja perhetutkimusten perusteella tämä 
yhteisesiintyminen selittyy suurelta osin geneettisillä tekijöillä, mikä viittaisi siihen, 
että useat diagnostisesti erotellut mielenterveyden häiriöt jakavat osan geneettisestä 
taustasta keskenään. Tätä tukee myös se, että osa sairauksien oireista, kuten 
kognitiivisten eli tiedonkäsittelyyn liittyvien toimintojen häiriöt, ovat samankaltaisia 
joskin vaikeusasteeltaan vaihtelevia useimmissa vakavissa mielenterveyshäiriöissä. 
Kognitiivisten toimintojen häiriöt ovat erityisen tavallisia skitsofreniaa sairastavilla. 
Ne ilmaantuvat potilailla jo ennen varsinaisen taudin puhkeamista, ja niitä esiintyy 
myös terveillä perheenjäsenillä. Kognitiivisten toimintojen häiriöt saattavatkin olla 
merkki geneettisestä alttiudesta sairauteen. Ne säilyvät läpi sairauden ja ennustavat 
usein huonompaa hoitotulosta. Tämä oli lähtökohtana oletukselle, että skitsofrenian 
geneettinen arkkitehtuuri olisi samankaltaisempi kehityksellisten sairauksien, kuten 
älyllisen kehitysvammaisuuden, kanssa kuin mitä aiemmin on oletettu. Tässä 
tutkimuksessa oletettiin erityisesti, että harvinaiset geneettiset muutokset, joihin 
liittyy suuri sairastumisriski, olisivat tärkeitä skitsofrenian geneettisessä etiologiassa. 
Harvinaisten suurikokoisten perimän rakenteellisten muutosten on pitkään tiedetty 
aiheuttavan normaalin kehityksen häiriöitä ja oireyhtymiä, kuten Prader-Willin tai 
velokardiofasiaalisen oireyhtymän. Tässä tutkimuksessa selvitettiin isokokoisten 
perimän kopiolukumuutosten osuutta skitsofrenian geneettisessä taustassa ja 
ominaisuuskissa, joiden oletimme heijastelevan hermoston kehityksen häiriötä.  
 
Tutkimuksessa tunnistettiin neljä perimän poistumaa eli deleetiota kromosomeissa 
1q21, 15q11.2, 15q13.3 ja 22q11.22, jotka assosioituivat skitsofreniaan. Kolme 
deleetioista ilmaantuvat toistuvasti, kun taas 22q11.22-deleetio on 
perustajamutaatio, joka on rikastunut väestöön erityisesti Suomessa Koillismaalla. 
Väestötasolla isojen deleetioiden kantajissa yleisesti havaittiin enemmän älyllisen 
kehityksen häiriöitä (älykkyysosamäärä alle 85) kuin henkilöissä, joilla ei havaittu 
isokokoisia deleetioita. Myös lievemmät oppimisvaikeudet, määriteltynä henkilön 
luokalle jääntinä olivat yliedustettuina suurien deleetioiden kantajissa. Kaikki neljä 
tunnistettua deleetiota assosioituvat vaihtelevaan ilmiasuun, jossa suurin vaikutus 
näyttäisi olevan juuri älyllisiin kykyihin. 22q11.22- deleetion alueellinen 
rikastuminen mahdollisti siihen liittyvien peittyvien ominaisuuksien tutkimisen. 
Neljä henkilöä kantoi kromosomin 22q11.22 deleetioita homotsygoottisesti. Heillä 
kaikilla on diagnosoitu skitsofrenia tai älyllisen kehityksen häiriö. Deleetio poistaa 
topoisomeraasi 3 beeta proteiinia koodittavan geenin (TOP3β). TOP3β proteiinin 
havaittiin muodostavan proteiinikompleksin FMRP:n (fragile X mental retardation 
protein) kanssa TDRD3 (Tudor domain containing 3) proteiinin välityksellä.  
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Tutkimuksen tulokset osoittavat, että pieni osajoukko skitsofreniaa sairastavista 
kantaa harvinaisia suuren sairastumisriskin geneettisiä muutoksia. Nämä muutokset 
on lisäksi jaettuja kehityksellisten häiriöiden kanssa. Tutkimus osoittaa, että 
geneettisesti eristäytyneet väestöt voivat tarjota edullisia tutkimusasetelmia 
erityisesti harvinaisten haitallisten geneettisten muutosten tunnistamisessa 
monitekijäisten sairauksien taustalla. Varsinkin muutoksiin liittyvien peittyvien 
vaikutusten havaitseminen voi olla helpompaa näissä väestöissä. 
 
Avainsanat: skitsofrenia, kognitiiviset toiminnot, kopiolukuvariaatiot, 
Perimänlaajuinen assosiaatiotutkimus 
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1 Introduction 
In addition to its vital life sustaining role, the higher level functions of the brain are 
fundamental to human behavior, intellect, cognition and are core features of the 
concept of humanity. Therefore disorders affecting these brain functions are so 
devastating and compromise the very existence of the person affected. Mental 
disorders have puzzled humanity for millennia, but their fundamental causes and 
underlying biology have remained a mystery. Historically, mental disorders have 
been separated from other medical illnesses because they affect the mind (Andreasen 
1997). Schizophrenia was recognized as its own disease entity and separated from 
manic-depressive illness and dementia in the elderly (later named as Alzheimer’s 
disease) 120 years ago by Emil Kraepelin (Andreasen 1995). However, since then 
the causes for schizophrenia and other mental disorders have remained unknown and 
until the discovery of first effective antipsychotic drugs in the 1950’s, people 
suffering from schizophrenia could not be treated efficiently. In the history of 
mankind, people with severe mental disorders have faced cruelty due to the lack of 
understanding and unjustified assumptions of the disease etiology (Brown 1997). 
Currently, even though some symptoms can be treated, other core features of the 
disorders remain, and in case of schizophrenia, individuals affected by it rarely 
achieve full recovery (Harrison et al. 2001, Robinson et al. 2004, Jaaskelainen et al. 
2013). Since schizophrenia onsets at a young age also the economic impact on 
society is enormous (Knapp et al. 2004). 
 
Today, 120 years after the clinical definition of schizophrenia and 60 years after the 
introduction of first efficient neuroleptic drugs the biological background of 
schizophrenia and other mental disorders is finally emerging. Based on evidence 
from pharmacological studies, schizophrenia has been considered as both a 
“dopamine disorder” and more recently a “glutamate disorder”, yet it has remained 
unclear how these are biologically related to the underlying causes of the disorder 
(Insel 2010). The heritability of severe mental disorders, including schizophrenia is 
among the highest for complex human diseases, and undisputedly refers to the 
biological nature of the disease (Sullivan et al. 2012). Consequently, one of the 
major drivers for the new biological insights has been the rapid development of 
genetic research technologies. These technologies have enabled the investigation of 
genetic variants genome-wide in high resolution and with adequate sample sizes 
without an a priori hypothesis of biological network or genes, but rather allowing 
the generation of novel hypothesis based on the genes and the networks identified. 
The governing idea underlying genome-wide association studies is the common 
disease common variant hypothesis. This hypothesis postulates that an individual’s 
Introduction 
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genetic risk for a disease is attributable to multiple genetic variants each contributing 
only a minor increase to the disease risk. According to this hypothesis majority of 
the genetic risk for common complex diseases is due to common ancestral variants 
that are shared across populations. That is, the genetic risk for these diseases is also 
shared across populations (Lander 1996, Risch et al. 1996). After the first successful 
genome-wide association studies (GWAS) published in 2005 for macula 
degeneration (Klein et al. 2005), thousands of genomic loci have been identified 
underlying various complex traits (www.genome.gov/GWAStudies).  
 
The first large-scale GWAS of schizophrenia were published in 2009 each including 
roughly 3000 patients (Purcell et al. 2009, Shi et al. 2009, Stefansson et al. 2009). 
These revealed associations with the major histocompatibility complex (MHC) on 
chromosome six. In addition, a polygenic score that consisted of multiple nominally 
associated common variants was found to underlie a significant portion of the 
genetic risk for schizophrenia. Supported by the polygenic risk score, the role of 
common low impact variants in schizophrenia seemed evident also in the genetic 
level and GWAS meta-analyses with larger sample sizes were conducted (Purcell et 
al. 2009). Currently, 108 loci for schizophrenia have been identified and one third of 
the variance in liability is estimated to be accounted for by mostly common genetic 
variants (Ripke et al. 2013, Schizophrenia Working Group of the Psychiatric 
Genomics 2014). Taken together the genetic studies support schizophrenia as a 
highly multifactorial disease resulting from the interplay between both genes and 
environment (Howes et al. 2014). 
 
Alongside the common disease common variant hypothesis, a major role for rare 
genetic variants has been suggested in schizophrenia. The common disease rare 
variant hypothesis argues that multiple rare genetic variants, each having relatively 
high penetrance, are major contributors for the genetic susceptibility to common 
diseases (Schork et al. 2009). The common disease rare variant hypothesis in mental 
disorders was strengthened by earlier genetic findings in other severe early onset 
developmental disorders including intellectual disability and autism. Even in 
schizophrenia the Velocardiofacial Syndrome (VCFS), caused by a micro-deletion 
on chromosome 22q11.2, is one of the highest known singular risk factors 
(Karayiorgou et al. 1995). There was also evidence for family specific high risk 
variants such as the balanced translocation disrupting DISC1 (Millar et al. 2000). 
Furthermore, the existence of rare high risk de novo variants is compatible with the 
evolutionary paradigm of reduced fecundity, increased mortality, and large portion 
of sporadic cases observed for schizophrenia. Even prior to the first GWAS results 
for common Single Nucleotide Polymorphisms (SNPs), rare recurrent large scale 
genomic Copy Number Variants (CNVs) were found to associate with a markedly 
Introduction 
 
 21  
 
increased risk for schizophrenia (International Schizophrenia Consortium 2008, 
Stefansson et al. 2008). The early findings have been since then replicated in 
multiple studies and today at least 15 rare CNVs are consistently associated with 
schizophrenia (Malhotra et al. 2012). Although important contributors to carrier’s 
individual genetic risk, the global impact of rare high risk CNVs is limited to a small 
percentage of patients. 
 
Although still in its early days, common biological themes have started to emerge 
from the genetic findings of schizophrenia and other mental disorders. Most 
importantly, schizophrenia appears to be as biological in origin as any somatic 
disorders and has a strong genetic component. Genetic architecture of schizophrenia 
follows a complex inheritance pattern that is governed by thousands of common 
variants: a pattern that is similar to many other complex traits including adult height 
and susceptibility to other complex diseases (Sullivan et al. 2012). Yet, also rare and 
de novo variants contribute to schizophrenia at least in some sub-groups of the 
patients (Owen et al. 2010). The schizophrenia associated genes are overrepresented 
with neuronal expressed genes and include synaptic gene-networks related to 
plasticity and synaptic transmission (Kirov et al. 2012, Fromer et al. 2014, Purcell et 
al. 2014, Schizophrenia Working Group of the Psychiatric Genomics 2014). Despite 
the clinical distinction between psychiatric disease entities, following Kraepelin’s 
idea from over century ago, the genetic evidence supports shared biological 
background across mental disorders, including schizophrenia, bipolar disorder, 
major depressive disorder, autism, attention deficit and hyper activity disorder 
(ADHD), and intellectual disability (Sullivan et al. 2012). Furthermore, the growing 
body of biological knowledge of not only severe mental disorders but also 
neurological disorders has begun to eliminate classical distinctions between 
psychiatric and neurological disease entities. This may have a profound impact in 
our way of conceptualizing and treating severe mental disorders in the future. 
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2 Review of the Literature 
2.1 Schizophrenia and related severe mental disorders  
2.1.1 Clinical features of schizophrenia 
 
There are currently no biomarkers for schizophrenia or for most other mental 
illnesses. They are syndromes and their diagnoses are based on combination of 
signs, symptoms, and outcome. The fact that most symptoms form a continuum with 
normality adds an extra layer of complexity for diagnosis, which is why the 
diagnostic criteria include thresholds for severity and duration. Schizophrenia was 
originally called dementia praecox, and it was separated from manic depressive 
illness and from dementia in elderly (Alzheimer’s disease) in the late 19
th
 century by 
Emil Kraepelin. The name schizophrenia, introduced by Bleuler in 1911, 
emphasizes severe fragmentation of thinking and personality associated with the 
disorder (Andreasen 1995). Schizophrenia has been considered a disorder of 
executive functioning of the brain that affects multiple separate domains 
(perception, inferential thinking, language, behavioral monitoring, conceptual 
fluency, emotional expression, and avolition). Schizophrenia is a multifactorial 
disease that is defined by symptoms that are commonly divided to positive, 
disorganized and negative symptoms. Positive symptoms are exaggerations of 
normal functions, such as hallucinations and delusions. Disorganized symptoms 
include bizarre behavior, disorganized speech and inappropriate affect. Negative 
symptoms are loss of normal functions, such as affective blunting, social anhedonia, 
and poverty of speech (Andreasen 1995).  
 
The diagnosis of schizophrenia is usually defined in the international research 
practice by the criteria specified in the Diagnostic and Statistical Manual of Mental 
Disorders. In this study the fourth edition (DSM-IV) has primarily been used to 
define schizophrenia (Table 1) (American Psychiatric Association 1994). In DSM-
IV the psychotic disorders are distinguished from each other by the duration, 
dysfunction, type of delusions and hallucinations, presence of affective symptoms, 
and associated substance use or medical condition. In clinical practice schizophrenia 
is diagnosed according to the criteria specified on the Tenth Revision of the 
International Classification of Diseases and Related Health Problems (ICD-10). The 
diagnostic criteria of ICD-10 and DSM-IV overlap on most part, but the criteria 
differ for example in the required duration of symptoms (one month in ICD-10 
versus six months in DSM-IV), emphasis given for the auditory hallucinations,   
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Table 1. DSM-IV diagnostic criteria for schizophrenia (American Psychiatric 
Association 1994) 
Criterion A. Characteristic symptoms: Two (or more) of the following, each present for a 
significant portion of time during a 1-month period (or less if successfully treated): 
Positive symptoms: 
A1: Delusions  
A2: Hallucinations  
A3: Disorganized speech  
A4: Grossly disorganized or catatonic behavior  
A5: Negative symptoms: 
 Affective flattening  
 Alogia 
 Avolition 
Only one Criterion A symptom is required if delusions are bizarre or hallucinations consist of a voice 
keeping up a running commentary on the person's behavior or thoughts, or two or more voices 
conversing with each other. 
Criterion B. Social/occupational dysfunction: For a significant portion of the time 
since the onset of the disturbance, one or more major areas of functioning such as work, 
interpersonal relations, or self-care are markedly below the level achieved prior to the onset (or when 
the onset is in childhood or adolescence, failure to achieve expected level of interpersonal, 
academic, or occupational achievement). 
Criterion C. Duration: Continuous signs of the disturbance persist for at least 6 months. This 6-
month period must include at least 1 month of symptoms (or less if successfully treated) that meet 
Criterion A (i.e., active-phase symptoms) and may include periods of prodromal or residual 
symptoms. During these prodromal or residual periods, the signs of the disturbance may be 
manifested by only negative symptoms or two or more symptoms listed in Criterion A present in an 
attenuated form (e.g. odd beliefs, unusual perceptual experiences). 
Criterion D. Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and Mood 
Disorder With psychotic Features have been ruled out because either (1) no Major Depressive, 
Manic, or Mixed Episodes have occurred concurrently with the active-phase symptoms; or (2) if 
mood episodes have occurred during active-phase symptoms, their total duration has been brief 
relative to the duration of the active and residual periods. 
Criterion E. Substance /general medical condition exclusion: The disturbance is not due to the 
direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical 
condition. 
Criterion F. Relationship to a pervasive Developmental Disorder: If there is a history of Autistic 
Disorder or another Pervasive Developmental Disorder, the additional diagnosis of Schizophrenia is 
made only if prominent delusions or hallucinations are also present for at least a month (or less if 
successfully treated). 
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distinction between schizoaffective disorder, and emphasis on the requirement for 
poor outcome in DSM-IV (Perälä 2013). 
 
There is significant heterogeneity in the combinations of symptoms in 
schizophrenia, and none of them are specific for schizophrenia (van Os et al. 2009). 
Although schizophrenia has been considered a unique entity, its diagnostic criteria 
have varied throughout the six editions of DSMs. The DSM-IV was recently 
updated to DSM-5 (Tandon et al. 2013). The core of the six diagnostic criteria (A-F, 
table 1) for schizophrenia have remained virtually the same and most people who 
met criteria for schizophrenia in DSM-IV will do so also in DSM-5. In DSM-5 at 
least two of criteria A need to be present in a patient, while prioritizing criteria A1-
A3, and the emphasis on the bizarreness of the delusions has been omitted. In 
addition the definition of negative symptoms has been clarified to “Negative 
symptoms, i.e. diminished emotional expression or avolition”. Also the criteria F has 
been slightly modified from DSM-IV and states in DSM-5: “ If there is a history of 
autism spectrum disorder or other communication disorder of childhood onset, the 
additional diagnosis of schizophrenia is made only if prominent delusions or 
hallucinations are also present for at least 1 month (or less if successfully 
treated).”(Tandon et al. 2013). 
 
The symptoms of psychotic disorders can be divided into five dimensions based on 
psychopathology: psychosis (positive symptoms), negative symptoms, cognitive 
impairment, and affective dysregulation including mania and depression dimensions. 
The dimensions for positive and negative symptoms seem to follow different paths 
over time and only the negative dimension is associated with neurocognitive 
alterations. The symptoms of different psychotic disorders, including schizophrenia, 
schizoaffective disorder, and bipolar disorder overlap in the five dimensions. 
Schizophrenia diagnosis is used for psychosis that is associated with few affective 
(related to mood) symptoms. In contrast, psychosis with fewer negative symptoms 
that is preceded by high level of affective symptoms is diagnosed as bipolar disorder 
or depression. Schizoaffective disorder lies between affective and non-affective 
psychosis (Figure 1)(van Os et al. 2009). 
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Figure 1. Diagnostic dimension of schizophrenia, schizoaffective disorder, and 
bipolar disorder. Modified from (van Os et al. 2009) 
DSM-5 has excluded the DSM-IV subtypes of schizophrenia and replaced them with 
dimensional assessment of eight psychopathological dimensions of schizophrenia. 
The aim in DSM-5 has been to emphasize the high level of heterogeneity in the 
combination and severity of symptoms, which are also known to vary over time 
among patients. Also, particularly supported by recent genetic evidence, the overlap 
and comorbidity between traditionally distinct diagnostic entities, is taken better into 
account with the dimensionality. In addition to the five criteria A of DSM-IV for 
schizophrenia (Table 1), the eight domains of dimensional assessment in DSM-5 
include depression, mania and impaired cognition. The domains are measured in a 
scale of zero to four: 0 (not present), 1 (equivocal), 2 (present, but mild), 3 (present 
and moderate), and 4 (present and severe). In comparison to DSM-IV, when an 
individual’s primary symptoms of psychosis (criteria A) score higher than two it can 
be considered to fulfill the DSM-IV criteria. In addition, the DSM-5 includes a 
dimension of cognitive functioning in the diagnostic assessment; however it is not 
included as a differential diagnostic symptom of schizophrenia. This is because, 
although, a marked portion of individuals with psychotic disorders have 
impairments over a range of cognitive domains, the impairments are similar in both 
affective (related to mood) and non-affective (not related to mood) psychoses, even 
though the impairment seems more severe in non-affective psychosis (Barch et al. 
2013, Tandon et al. 2013). 
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2.1.2 Cognitive functioning in schizophrenia  
Schizophrenia is associated with generalized impairment of various cognitive 
functions, and patients perform on average one standard deviation below unaffected 
controls (Heinrichs et al. 1998, Mesholam-Gately et al. 2009, Fioravanti et al. 
2012). Cognitive functions are defined as the processes of acquiring, processing, 
storing of, and acting upon information. They are assessed by standardized 
neuropsychological test methods that measure, for example, memory, global 
cognitive abilities, verbal skills, and executive functioning. The impairments in 
schizophrenia patients are already broadly present during the premorbid period and 
the first episode and they remain similar throughout the later phases of illness 
(Woodberry et al. 2008, Mesholam-Gately et al. 2009, Reichenberg et al. 2010). 
Cognitive impairments are more severe among patients with an early onset disease 
(Rajji et al. 2009). Relatives of schizophrenia patients perform intermediate between 
schizophrenia patients and controls in neurocognitive measures, suggesting that 
these deficits indicate a genetic predisposition to the disease (Faraone et al. 2000, 
Sitskoorn et al. 2004, Toulopoulou et al. 2010). Although there is significant 
heterogeneity in neurocognitive dysfunction among patients (Kremen et al. 2004), 
many consider it as a core feature of schizophrenia (Elvevag et al. 2000). However, 
it is still not included as a characteristic feature even in the DSM-5 diagnostic 
criteria. This is mainly because, although cognitive impairment is acknowledged to 
be present in large portion of cases, it does not distinguish between schizophrenia 
and other psychiatric disorders (Barch et al. 2013, Tandon et al. 2013). Some studies 
have reported weaker school performance and delays in early developmental mile 
stones in children who later develop schizophrenia (Jones et al. 1994, Sorensen et al. 
2010). Patients with schizophrenia in Finland have not been shown to deviate in 
academic factors of school performance (Cannon et al. 1999). However, there is a 
paucity in progressing to high school and individuals who are diagnosed with a 
psychiatric illness have more often repeated grades in school (Isohanni et al. 1998, 
Cannon et al. 1999).  
2.1.3 Neurodevelopmental model of schizophrenia  
The prevailing and widely accepted hypothesis is that schizophrenia is a 
neurodevelopmental disorder that results as an end state of abnormal developmental 
processes that have started long before the onset of the disease. A significant body 
of evidence supports the gradual development of schizophrenia, although the risk 
factors are often nonspecific for schizophrenia but are rather associated with risk to a 
broad range of psychotic and developmental disorders (Rapoport et al. 2005, Insel 
2010, Rapoport et al. 2012). Individuals who later develop schizophrenia have lower 
cognitive and motor performance, and will already have had more psychotic 
symptoms in childhood. Schizophrenia is associated with pre- and perinatal risk 
factors, including prenatal infections, famine during gestational period and placental 
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pathology. Consistently, also low birth weight is a significant risk factor for 
schizophrenia. Other premorbid risk factors include urban environment, ethnic 
minority, and childhood trauma, but as is the case for other risk factors these are 
diagnostically non-specific. The developmental model of schizophrenia is further 
supported by evidence from longitudinal neuroimaging studies that suggest 
progressive grey and white matter abnormalities occurring particularly in the 
prefrontal and temporal cortices of patients with schizophrenia. Finally the 
developmental model is supported by recent genetic findings that link schizophrenia 
with other developmental disorders. The premorbid indicators of schizophrenia are 
subtle and non-specific, but the consistency of the findings support that psychosis 
does not occur in a completely healthy brain (Rapoport et al. 2005, Insel 2010, 
Rapoport et al. 2012). 
2.1.4 Prevalence of schizophrenia 
Schizophrenia, as most mental disorders, has a peak age of onset in the second and 
third decades of life (Andreasen 1995, Pedersen et al. 2014). The prevalence and 
incidence estimates for schizophrenia vary between studies depending on what 
diagnostic criteria were used and whether the study was conducted as a register or 
community survey study (Pedersen et al. 2014). The global incidence for 
schizophrenia is relatively low, with only 15.2 per 100 000 individuals per year 
reported (McGrath et al. 2004). The median global lifetime prevalence of 
schizophrenia is 0.4% but the prevalence estimates vary over six-fold across studies 
(Saha et al. 2005, McGrath et al. 2008). A recent register based study conducted on 
a Danish population concluded a lifetime cumulative incidence (i.e. the probability 
of being treated before 50 years of age) of 1.73% for males and 1.24% for females, 
and a lifetime prevalence of 1.93% for males and 1.56% for females. Over 3.5% of 
population was treated because of schizophrenia and related disorders (Pedersen et 
al. 2014). The prevalence for schizophrenia in Finland is high (0.87%-2.2%) and the 
lifetime prevalence for all psychotic disorders is over 3% (Lehtinen et al. 1990, 
Hovatta et al. 1997, Cannon et al. 1998, Arajarvi et al. 2005, Perala et al. 2007). The 
risk for the disorder varies regionally (Hovatta et al. 1997, Haukka et al. 2001, 
Perala et al. 2007). In general there is a south-north and west-east gradient with odds 
ratios (ORs) of 4.0 and 7.2, respectively (Perala et al. 2007). Among the highest 
risks is observed in the North-Eastern isolate of Kuusamo with a three-fold age 
corrected lifetime risk for schizophrenia compared to rest of Finland (Hovatta et al. 
1997). Globally, the life time morbid risk for schizophrenia is 0.72% (Saha et al. 
2005). The regional variation in the life time risk for schizophrenia in Finland may 
reflect regional genetic, environmental, and sociodemographic differences (Perala et 
al. 2008). 
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2.1.5 Genetic background of schizophrenia  
Schizophrenia is a highly heritable disorder with heritability estimates in twins 
ranging up to 80% (Sullivan et al. 2003). In Finland the corresponding estimate in 
twins is 83% (Cannon et al. 1998). In fact, family history is the strongest single risk 
factor for schizophrenia (Mortensen et al. 1999, Sullivan 2005). The population 
attributable risk is still modest, however, and a marked portion of schizophrenia 
patients do not have a family history of schizophrenia (Mortensen et al. 1999). 
Schizophrenia is associated with a broad range of mental disorders in first degree 
relatives, which suggests that the genetic factors contributing to these disorders are 
also shared (Lichtenstein et al. 2009, Mortensen et al. 2009). Recent genetic studies 
including those results that are specifically presented in this thesis directly support 
there being a shared genetic etiology between a broad range of mental and 
developmental illnesses. Schizophrenia heritability accounted by common SNPs in 
case control setting is estimated to be close to 32% (Ripke et al. 2013). Furthermore, 
there is a significant genetic correlation calculated from common SNPs between 
schizophrenia and bipolar disorder (0.68), major depressive disorder (0.43), and 
autism spectrum disorders (0.16) (Cross-Disorder Group of the Psychiatric 
Genomics et al. 2013). In terms of co-heritability with schizophrenia, this would 
respectively translate into 15%, 8.7%, and 3%. (Cross-Disorder Group of the 
Psychiatric Genomics et al. 2013) While the strongest correlation with common 
variants in schizophrenia is with affective psychosis, rare genetic variants associated 
with schizophrenia are often shared with developmental disorders, including 
intellectual disability and autism spectrum disorders (Malhotra et al. 2012). 
Moreover, both in schizophrenia and autism the association with potentially high 
impact de novo variants is driven by cases with cognitive deficits, whereas cases 
with normal cognitive abilities do not differ from controls (Fromer et al. 2014).  
 
2.1.6 Genetic background of Intellectual impairment  
The impairment in cognitive functions is a distinctive feature shared between 
schizophrenia and some developmental disorders. Considering the genetic 
architecture of intellectual deficit or learning disabilities more broadly, the 
cumulative evidence would support these disorders as complex and genetically 
heterogeneous. Cases with severe intellectual disability commonly do not have 
family history of low intelligence quotient (IQ) and their close relatives do not differ 
from general population in their cognitive abilities, suggesting that there is 
heterogeneity in the genetic architecture of intellectual disability with the most 
severe forms having de novo or recessive origins. On the other hand, the normal 
range of intelligence has a significant genetic component that consists of multiple 
genes with small effects (Davies et al. 2011). Cases with mild intellectual disability 
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have more affected relatives, which implies that mild intellectual disability is part of 
the main IQ distribution and is genetically driven by a polygenic signal (Nichols 
1984). A study on Swedish school children with mild intellectual disability of 
unknown cause, reported that half of the children had at least one first degree 
relative with borderline or subnormal intelligence according to school history and 
the condition was associated with neurological and psychiatric abnormalities 
(Hagberg et al. 1981). Similarly, standardized mathematics and reading scores 
correlate with each other, and specific learning difficulties defined as test scores 
below one standard deviation in arithmetic, reading, and spelling disorders often 
coexist in individuals suggesting common biological background of specific 
scholastic skill levels (Landerl et al. 2010, Davis et al. 2014). These scholastic skill 
levels are highly heritable and approximately one half of their correlation is 
accounted by shared genetic effects referred to as “generalized genes” (Kovas et al. 
2007, Davis et al. 2014). Collectively, it seems that genes affecting normal variation 
in learning abilities also affect learning disabilities and these effects are shared 
across different scholastic domains (e.g. mathematical and verbal skills) (Plomin et 
al. 2005). Consistently, mild intellectual disability, but not severe, is associated with 
lower educational and socioeconomic level of parents of patients (Camp et al. 1998, 
Stromme et al. 2000, Chapman et al. 2002, Heikura et al. 2008). 
 
The prevalence of both mild (IQ < 70) and severe (IQ < 50) intellectual disability in 
northern Finland is approximately twice the values measured in Sweden with a 
combined prevalence of 1.2% (Rantakallio et al. 1986). During 20 years the 
prevalence have remained same, although there has been a shift from severe towards 
mild intellectual disability (Heikura et al. 2003). Also the parental socioeconomic 
and educational level is associated with intellectual disability in Northern Finland 
(Heikura et al. 2008). Intellectual sub-normality (IQ: 71-85) has a prevalence of 
1.4% in Northern Finland. Of children born in 1966 3.8% were below the 
appropriate school grade for their age and of these 66% had IQ above 85 
(Rantakallio et al. 1986). Furthermore, a possible causal prenatal, perinatal or 
postnatal factor could be assigned less often for mild (IQ<70) and borderline (IQ< 
86) intellectual disability than for severe intellectual disability (IQ<50) (Rantakallio 
et al. 1985, von Wendt et al. 1987). When taken together the evidence would 
support a complex polygenic architecture for intellectual disability in Finland that 
might also be shared with other severe mental disorders, such as schizophrenia. 
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2.2 Human genome 
2.2.1 Structure  
The genetic code is encrypted to an alternating sequence of four organic bases: 
Adenine (A), Cytosine (C), Guanine (G), and Thymine (T) that are joined together 
by 2’-deoxyribose diphosphoester chain to form deoxyribonucleic acid (DNA). Two 
complementary DNA strands, running in opposite directions, are bound by hydrogen 
bonds, generating a double helix, where A pairs only with T and C only with G 
(Figure 2) (Watson et al. 1953). A diploid human genome consists of approximately 
6.5 billion base pairs that are organized into 23 pairs of nuclear chromosomes and 
into 16.5 kb circular mitochondrial DNA (mtDNA). Of the nuclear chromosomes, 
22 pairs are called autosomes and the 23
rd
 pair comprises the sex chromosomes 
which occur either as two X chromosomes (females) or an X and a Y (males). Half 
of individual’s diploid genome is inherited maternally and the other half paternally.  
 
 
Figure 2. The structure of DNA and its organization to chromosomes (modified 
from www.genome.gov/Glossary). 
The first draft of the human genome was published in 2001 (Lander et al. 2001, 
Venter et al. 2001), and the first release of the completed reference sequence of 2.85 
billion nucleotides in 2004 (NCBI Human Genome Build 35) (International Human 
Genome Sequencing Consortium 2004). The definition of a gene has varied over 
time from a unit of inheritance that carries a characteristic from parent to child into 
being associated with instructions for building proteins or as being discrete physical 
parts of a sequence transcribed into messenger ribonucleic acid (mRNA) (Pearson 
2006). Currently a more broad view of the gene has been adopted and it can be 
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defined as ”a union of genomic sequences encoding a coherent set of potentially 
overlapping functional products” (Gerstein et al. 2007). Approximately only 1.2% 
of the genome encodes for proteins, it is termed the exome and it is distributed into 
roughly 20,000 protein coding genes (Ng et al. 2009, Durbin et al. 2011, Encode 
Project Consortium et al. 2012, Harrow et al. 2012). The protein coding genes are 
fragments of DNA that contain the information for the amino acid sequence of a 
protein. The non-coding regions between the coding exons within a gene are termed 
introns. Intronic sequences are removed from mRNA in a process known as splicing 
that takes place prior to protein translation. Multiple different transcripts called 
isoforms can be formed from one gene by alternative splicing. The number of 
protein-coding transcripts is over four-times the number of protein-coding genes 
(Gencode, version 19, July 2013, http://www.gencodegenes.org). The remaining 
99% of the genome was previously considered to be largely nonfunctional. 
However, the bulk of this so called “junk DNA” is now known to have wide spread 
functional elements with important biological roles delineated in the Encyclopedia 
of DNA elements (ENCODE) project (Encode Project Consortium et al. 2012). In 
addition to the protein coding genes, thousands of non-coding RNA genes (Djebali 
et al. 2012, Harrow et al. 2012), regulatory(Sanyal et al. 2012, Thurman et al. 
2012), and protein interacting elements (Neph et al. 2012) exist in the human 
genome. It is estimated that at least 80% of the genome participates in at least one 
biochemical function (Encode Project Consortium et al. 2012).  
 
Any two individuals are 99.9% identical with each other in their DNA (Przeworski 
et al. 2000, Reich et al. 2002). Still both sequence and structural variation exists in 
the genome and results in much of the differences seen between individuals. These 
genetic variants can also be used as genetic markers in the mapping of genomic 
regions that contribute to the phenotypic variation (Altshuler et al. 2008).  
 
2.2.2 Single nucleotide polymorphisms  
SNPs have been the most accessible and well characterized form of genetic 
variation. In parallel with the Human Genome Project, a project to identify and 
catalog common human variation was initiated (Sachidanandam et al. 2001). The 
goal of the SNP Consortium was to achieve a comprehensive view of variation that 
could then be systematically used to explore associations for human traits. The 
number of SNPs with minor allele frequency of over 1% is around 10 million (Reich 
et al. 2003). Consequently, the majority of heterozygous sites in each individual are 
due to common variants even though collectively most varying sites are rare 
(Sachidanandam et al. 2001, International HapMap Consortium 2005, Durbin et al. 
2011). Re-sequencing of thousands of individuals has uncovered a multitude of new, 
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mostly rare, variants (Wheeler et al. 2008, Durbin et al. 2011, Genomes Project 
Consortium et al. 2012). The current dbSNP release includes over 60 million 
variants (dbSNP Build 138 for Human, Date: 23 July 2013, 
http://www.ncbi.nlm.nih.gov/projects/SNP/).  
 
The substitution mutation rate in the human genome is estimated to be ~1.2×10
-8
 per 
base per generation and correlates strongly with paternal age (Kong et al. 2012). The 
majority of de novo single nucleotide mutations are paternal in origin (Kong et al. 
2012). SNPs have a low rate of recurrent mutation, which is why common ancestral 
SNPs have generally singular origin in the ancestral human populations and are 
shared between populations. The frequencies can however vary substantially across 
populations (International HapMap Consortium 2003, Hinds et al. 2005, 
International HapMap Consortium 2005). In contrast to common variants, low-
frequency variants show significant geographic differentiation (Genomes Project 
Consortium et al. 2012). Rare variants are enriched with functional variants that 
directly change the amino acid sequence (Genomes Project Consortium et al. 2012). 
Still, each individual carries approximately 100 Loss of Function (LoF) variants, of 
which 20 are in the homozygous state (MacArthur et al. 2012).  
 
2.2.3 Structural variation in human genome  
Genetic variants that alter genetic structure are broadly defined as structural 
variation. They can be further categorized into balanced changes, such as inversions 
and translocations or as changes that alter the copy number of the DNA, termed 
copy number variants (CNVs). CNVs are in turn further categorized as deletions and 
duplications (Figure 3). The size variation of structural variants forms a continuum 
in the genome ranging from single bases to whole chromosomes, but the term is 
usually reserved for variation of over 1 kb in size (Feuk et al. 2006, Hurles et al. 
2008). CNVs vary significantly in size ranging up to several mega bases (Iafrate et 
al. 2004). The larger (>100 kb) CNVs tend to be rare, although around half of them 
are still observed in multiple individuals (Iafrate et al. 2004, Sebat et al. 2004, Sharp 
et al. 2006). In deed, it has been estimated that any two individuals differ by 11 
CNVs of over 100 kb in size (Sebat et al. 2004). Large scale CNVs, as a class of 
variants, account for most bases that vary in the genome (Wheeler et al. 2008).  
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Figure 3. Description of types of large scale structural mutations in the genome 
(modified from www.genome.gov/Glossary). 
 
The extent of large-scale CNVs in the human genome outside the context of cancer 
and chromosomal abnormalities began to be realized in 2004 (Fredman et al. 2004, 
Iafrate et al. 2004, Sebat et al. 2004). A first comprehensive map of CNVs in the 
human genome was generated in 2006 with over 1,447 sites varying in copy number 
(Redon et al. 2006). Currently, thousands of CNV regions have been recognized and 
they encompass a marked portion of the genome ranging from early estimates of 
12% to current 3% (Redon et al. 2006, Conrad et al. 2009). Similarly to sequence 
variants common CNVs are shared across populations whereas the rare ones are 
often observed in a single population (Mills et al. 2011). CNVs have been 
demonstrated to have impact on biological processes including gene expression and 
disease susceptibility (Stranger et al. 2007, Hurles et al. 2008). While numerous 
functional sequences including genes and conserved sequences are overlapped by 
CNVs (Iafrate et al. 2004, Tuzun et al. 2005, Redon et al. 2006, Conrad et al. 2009), 
both deletions and duplications are generally biased away from genes (Conrad et al. 
2006, Redon et al. 2006, Conrad et al. 2009). Moreover, this paucity is stronger 
among deletions and common CNVs (Conrad et al. 2009). Deletions are on average 
also shorter than duplications (Redon et al. 2006).  
 
The CNV mutation rate is estimated to be 3×10
-2
 per haploid genome per generation 
(Conrad et al. 2009). CNVs tend to cluster in genomic regions containing 
interspersed duplications, called segmental duplications, or low copy repeats (LCR) 
(Fredman et al. 2004, Iafrate et al. 2004, Sebat et al. 2004, Sharp et al. 2005, Tuzun 
et al. 2005, McCarroll et al. 2006, Redon et al. 2006). The LCR size, sequence 
identity, and orientation, as well as the distance between two LCRs affect the 
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probability for miss-alignment during meiosis via nonallelic homologous 
recombination (NAHR) (Stankiewicz et al. 2002, Redon et al. 2006). 
Intrachromosomal segmental duplications are also more likely to be associated with 
CNVs than interchromosomal segmental duplications (Redon et al. 2006). 
Approximately 5% of the human genome contains LCRs. LCRs span from one to 
hundreds of kilobases and they share a high (>90%) sequence identity (Bailey et al. 
2001, Cheung et al. 2001, Eichler 2001, Lander et al. 2001, International Human 
Genome Sequencing Consortium 2004). LCRs contain both coding and non-coding 
sequences and are dispersed into the entire genome, but are enriched to 
pericentromeric and telomeric regions (Bailey et al. 2001). LCRs are known 
mediators of clinically significant chromosomal rearrangements (Lupski 1998, Ji et 
al. 2000, Stankiewicz et al. 2002), including Prader-Willi/Angelman syndrome 
(PWS/AS) (Amos-Landgraf et al. 1999, Christian et al. 1999), VCFS (Edelmann et 
al. 1999, Shaikh et al. 2000), and Williams-Beuren syndrome (Francke 1999, 
Peoples et al. 2000). Breakpoint analysis of 1000 genomes sequence data suggests 
that large scale CNVs are primarily formed via NAHR (Mills et al. 2011). The 
majority of smaller scale CNVs are formed by non-homolougs end joining (NHEJ) 
or microhomology-mediated break-induced replication (MMRBI), while small 
insertions are attributable for transposition activity (Mills et al. 2011). 
 
Several lines of evidence support deletions as a class of variants that are enriched 
with disruptive mutations, and are under negative selection. A marked portion of 
detected deletions are rare (Conrad et al. 2006, Conrad et al. 2009). Furthermore, the 
deletion size is negatively correlated with its frequency and the majority of common 
deletions are small (<10kb) (Conrad et al. 2006, Locke et al. 2006, McCarroll et al. 
2006). Also the length and frequency of deletions varies in populations of different 
ages. Even though there are more deletions in older populations (African ancestry) 
they tend to be shorter compared to younger populations (European ancestry), 
(Conrad et al. 2006, Conrad et al. 2009). Also, compared to duplications, deletions 
are markedly (one-third) shorter (Redon et al. 2006). Fitted statistical models 
suggest that especially exonic deletions are subject to purifying selection (Conrad et 
al. 2009). Consistently, particularly low frequency deletions appear in multiple 
haplotypes suggesting that the deletion events have occurred recurrently as to the 
deletions inherited from a singular ancestral event (Conrad et al. 2006). High 
frequency deletions are clustered away from coding regions (Mills et al. 2011). 
Furthermore, compared to duplications, a lower portion of deletions involve genes 
(Redon et al. 2006, Conrad et al. 2009). For duplications the evolutionary constraint 
is understood to a lesser extent. The existence of gene families, and based on 
genomic comparisons between species, such as humans and great apes (hominoids), 
it is evident that gene duplications have provided a substrate for the evolution of 
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new gene functions and have been subject to positive selection pressure (Fortna et 
al. 2004, Hurles 2004). 
 
2.2.4 The extent of linkage disequilibrium  
During meiosis chromosomes exchange genetic material. This genetic 
recombination creates new combinations of alleles in an individual, called 
haplotypes. When two nearby variants are inherited together more often than what 
would be expected by chance, they are said to be in linkage disequilibrium (LD). 
That is, the two co-inherited variants are not segregated independently in a 
population and LD exists because of the shared ancestry of contemporary 
chromosomes. In general, the likelihood for recombination increases with the 
distance between two loci. However, the recombination rate is unevenly distributed 
in the genome with some regions being more prone for recombination than others, 
consequently called recombination hotspots (Jeffreys et al. 2001). This results in a 
block like structure of 1-100 kilobase (kb) segments of DNA (termed haplotype 
blocks or haploblocks) each with limited allelic diversity and high LD separated by 
recombination hotspots of low LD (Daly et al. 2001). Although the genome is 
fragmented into short LD blocks by recombination, weaker long range LD also 
exists between the blocks weakening with distance. Within the haplotype block, LD 
is disrupted primarily by new mutation events, which is why they typically include 
only few haplotypes (Figure 4) (Daly et al. 2001, Patil et al. 2001, Reich et al. 2001, 
Gabriel et al. 2002).  
 
LD can initially extend over larger genomic distances, but decays gradually over 
time by recombination. LD depends on demographic history, stochastic events and 
functional constraint (Hinds et al. 2005). The haploblocks are approximately 50% 
shorter in populations of African ancestry compared to European and Asian 
populations, and haplotype diversity is greatest in African populations (Reich et al. 
2001, Gabriel et al. 2002, De La Vega et al. 2005). However, the block boundaries 
as well as the underlying haplotypes are largely shared across populations with those 
populations of African ancestry having more private haplotypes than others (Gabriel 
et al. 2002, De La Vega et al. 2005). A direct consequence of LD is that it enables 
the prediction of an allele of a variant based on the genotype of another without the 
need to genotype them both. In other words most of the haplotype diversity and 
genetic variation can be tagged by selecting a group of informative SNP markers, 
called tag SNPs (Hinds et al. 2005). Most of the genomic variation can be captured 
with common haplotypes and the incomplete correlation with missed variance can 
be overcome by increasing sample size (Gabriel et al. 2002). Two commonly used 
measures for pairwise LD are squared correlation coefficient between two alleles (r
2
) 
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and D’-value. The D’-value is a normalized measure of linkage disequilibrium (D), 
it is defined as 1 in the absence of recombination and it declines only due to 
recombination and recurrent mutation (Lewontin 1964, Daly et al. 2001, 
International HapMap Consortium 2005). 
 
 
Figure 4. Haplotype block structure (A), and haplotypes (B) for the gene encoding 
for TCF4 (chr18: 51.05-51.41 Mb, NCBI build 36) in HapMap CEU-individuals, for 64 
randomly selected SNPs from HapMap phase II and III, release 28, a view from 
Haploview software (Barrett et al. 2005). A) The relative position for each SNP is 
presented atop. The LD is colored according to D’ estimates and blocks are defined 
according to that described by Gabriel et al (Gabriel et al. 2002). B) Haplotypes with 
corresponding frequencies are presented for each block. Thick line connections of > 
10%, and thin lines connections of > 1%. In the crossing area multiallelic D’ is shown.  
An effort to characterize the pattern of common sequence variation in the human 
genome was undertaken by the International HapMap project 
(http://hapmap.ncbi.nlm.nih.gov/)(International HapMap Consortium 2003). In the 
first phase of the project approximately one million SNPs were characterized, and 
their frequencies and the co-inheritance between them were determined in four 
different populations (Caucasian represented by central Europeans in Utah-CEU; 
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Asian represented by Han Chinese from Beijing-CHB and Japanese from Tokyo-
JPT, and African represented by the Yoruban from Nigeria-YRI) (International 
HapMap Consortium 2005). In phase II the HapMap project included 3.1million, 
roughly one third of all common (minor allele frequency, MAF above 0.05) SNPs, 
improving the original resolution of the map (Frazer et al. 2007). In the latest 
version, Phase III HapMap sample sizes have been increased and additional seven 
populations were included into the study (International HapMap et al. 2010). The 
HapMap project has provided the scientific community a publically available 
resource of validated SNPs and with information of the genomic landscape in 
different populations that can be used as a tool in genetic mapping studies of 
complex traits. 
 
The extent of LD in a given population depends on the effective population size and 
the age of the population. Recombination is the major source for decay of LD, thus 
populations of recent ancestry and small founder population have longer stretches of 
LD. However, the LD maps are generally very similar between populations (De La 
Vega et al. 2005, Service et al. 2006). In a study by Service and coworkers (Service 
et al. 2006) a young subisolate of Kuusamo was found to have the most extensive 
LD among 11 European descendent isolates studied. The authors concluded that 
isolate populations could be a benefit to GWAS studies because less assayed SNPs 
are needed to tag the allelic diversity of the isolate population.  
 
The evolutionary history of common CNVs, sometimes referred to as copy number 
polymorphisms (CNPs), is similar to that of common SNPs (Conrad et al. 2009). 
Common, generally small scale (< 10 kb) deletions, located outside LCRs often 
descend from a single ancestral event, are shared between populations, are in LD 
with nearby SNPs, and exist also in a homozygous state (Hinds et al. 2006, Locke et 
al. 2006, McCarroll et al. 2006, Redon et al. 2006, Mills et al. 2011). Furthermore, 
similarly to SNPs, the extent of LD is lower in African ancestry population 
compared non-African populations (Redon et al. 2006). Even so, the extent of LD is 
still however lower between CNVs and SNPs than for two neighboring SNPs 
(Redon et al. 2006). Rare CNVs are also less well tagged by SNPs (Conrad et al. 
2009). Less than 5% of SNPs that associate with complex traits tag a known CNV. 
Moreover, since the majority of common CNVs can be measured indirectly with tag 
SNPs, common CNVs are not likely to provide a significant additional contributions 
to explain the heritability of complex traits other than by SNP association studies 
(Conrad et al. 2009), as will be discussed in the next section. 
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2.3 Genetic mapping of complex traits 
2.3.1 Estimating the contribution of genetic factors in a trait  
An obvious cornerstone of genetic analysis is the hypothesis that variance within a 
given trait is influenced by genetic factors. If a trait has a heritable component, 
individuals of close kinship, i.e. those who share the largest part of their DNA, 
resemble each other more closely than individuals with more distant kinship or no 
familial relation. An example is the genetic risk for a given disorder. If genetic 
factors do play a role in the vulnerability to a given disroder, close relatives of a 
patient would be at increased risk and the risk would decrease towards the general 
risk in a population for the more distant relatives as a function of decrease in genetic 
sharing. Family studies alone are not, however, sufficient to determine if the familial 
aggregation is due to shared genetic or shared environmental factors. For dissecting 
the genetic component of a trait, twin and adoption studies are needed. The 
difference in the concordance rate between monozygotic (MZ) and dizygotic (DZ) 
twin pairs provides an estimate of the extent of the genetic component in a trait. 
Adoption studies on the other hand, enable the estimation of the difference in risk 
between biological and non-biological siblings of both affected and unaffected 
parents, which provides an estimate of the relative contributions of shared 
environmental and genetic factors (Boomsma et al. 2002). 
 
2.3.2 Searching for gene variants contributing to complex traits  
The allelic spectrum of genetic variants in the human genome ranges from 
singletons to very common variants with a minor allele-frequency of ~50%. 
Different frequency bins are likely to be very different with regard to an individual 
variant’s impact on explaining variation in human traits and disorders (Figure 5). 
Natural selection controls the frequency of mutations that cause severely deleterious 
diseases, which is why severe Mendelian disorders tend to be caused by rare variants 
(Altshuler et al. 2008). Common variants with strong deleterious effects are unlikely 
to exist in complex diseases because if they did they would have most likely been 
identified by now (Manolio et al. 2009). On the other hand, common diseases are 
typically late onset diseases and have low impact on reproductive fitness, which is 
why variants causing them can increase to higher frequencies (Altshuler et al. 2008). 
Some current disease causing alleles could have been advantageous previously in 
human history, such as some autoimmune predisposing alleles, or balancing 
selection that can act on the causative alleles, such in sickle-cell anemia and malaria 
resistance (Jostins et al. 2012). Depending on the frequency bin and assumed 
impact, different methods and study designs are adopted in genetic studies. While 
the rare variants are tackled systematically by sequencing, common variants can be 
efficiently interrogated by genome-wide SNP arrays (GWAS). 
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Figure 5. Expected relative risks associated with genetic variants with different 
allele frequencies. The dashed lines confine the targets of genetic studies (Modified 
from(McCarthy et al. 2008, Manolio et al. 2009) 
The search for causal variants that influence a trait is termed genetic mapping. In 
principle genetic mapping can be conducted either directly by testing each 
potentially causative variant against a trait, or indirectly by relying on LD between 
nearby variants (Collins et al. 1997). A systematic approach that utilizes naturally 
occurring DNA variations as generic markers to build up a linkage map of the 
human genome and systematically trace inheritance in families was proposed in the 
1980s (Botstein et al. 1980). Linkage studies proved early on to be successful in 
identifying gene loci for Mendelian diseases, such as Huntington’s disease (Gusella 
et al. 1983). Currently, thousands of phenotype-causing mutations are known 
(http://www.ncbi.nlm.nih.gov/omim). Linkage studies have been largely 
unsuccessful, however,  in identifying gene variants for common forms of common 
traits in humans (Altshuler et al. 2008). 
 
Candidate gene driven association studies emerged alongside genome-wide linkage 
studies. In association studies, rather than studying the transmission in pedigrees, 
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differences in allele frequencies are compared between cases and controls. If an 
allele or a genotype has a higher frequency among cases this can be interpreted as 
evidence that the allele is associated with the trait studied. Association analysis is 
carried out for sample sets that have been ascertained from a population. For this 
reason, it requires denser map of genetic markers to interrogate haplotype diversity 
compared to those used in linkage studies tracing transmission within families. 
Association studies were limited to small genomic regions and candidate genes for 
technical reasons for long time. Although there are examples in which the candidate 
gene approach led to the identification of confirmed associations, most of the 
hundreds of associations reported are not robust and consistently replicated. The 
inability to replicate early genetic associations has been affected by weak genetic 
effects, small sample sizes, and population stratification (Hirschhorn et al. 2002). 
Exceptions include associations, between APOE and Alzheimer’s disease 
(Strittmatter et al. 1993), Factor V Leiden and deep vein thrombosis (Bertina et al. 
1994), and PPARγ and type II diabetes (T2D) (Altshuler et al. 2000) as examples.  
 
2.3.3 Genome-wide association studies of complex traits  
The majority of common complex disorders have significant genetic components 
(Lander et al. 1994). During the past decade GWAS studies have revolutionized 
genetic mapping and hundreds of loci for multiple common human disorders and 
complex traits have been identified (Figure 6), such as for Crohn’s disease (Jostins 
et al. 2012), T2D (Morris et al. 2012), adult height (Lango Allen et al. 2010), and 
schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics 2014). 
The grounding hypothesis of GWAS is the common disease common variant 
hypothesis which postulates that the genetic risk in an individual is attributable to 
the combination of many high frequency variants, each of which only marginally 
increase the risk for the disorder (Risch et al. 1996). A significant portion of 
common variation (~10 million SNPs) across populations can be captured by 
assaying several hundreds of thousands to a few millions of variants and testing 
them for association with a condition indirectly in a large case-control setting 
(Gabriel et al. 2002, Frazer et al. 2007). One of the early findings obtained from 
GWAS studies was that the effect sizes contributing to the associations are typically 
small (OR < 1.5) (Altshuler et al. 2008). A consequence of this is that large sample 
sizes are required to compensate for the low effect sizes. Since large numbers of 
variants are tested and there is a low prior probability for any one marker to be 
associated, this adds up to a required genome-wide significance threshold of p= 
5×10
-8
. This corresponds to the number of independent loci in the genome. 
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Figure 6. Published Genome-Wide Associations with p ≤ 5×10-8 up to December 
2012 for 17 trait categories. (Modified from www.genome.gov/GWAStudies)  
Even though multiple genetic risk loci have been identified for various human traits 
and diseases, a significant portion of the heritable susceptibility still remains to be 
assigned for specific gene variants. Although the genetic architecture likely varies 
from trait to trait, much of this so called “missing heritability” is likely to be 
explained by as yet undiscovered common variants that have only modest effects 
and which can only be detected in ever increasing sample sizes. It is also plausible 
that rare variants, gene-gene and gene-environment interactions account for some 
portion of the undefined genetic risk (McCarthy et al. 2008, Manolio et al. 2009). 
 
2.3.4 Rare variants in complex diseases  
Collectively, rare variants outnumber common variants in the human genome 
(Genomes Project Consortium et al. 2012). Rare variants are enriched with non-
neutral functional and deleterious variants supportive of them having a significant 
role also in explaining the variation of complex diseases (Li et al. 2010, Kiezun et 
al. 2012). Analysis of rare variants is hindered exactly because of the rarity of the 
variants, which limits statistical power (Kiezun et al. 2012). Rare sequence variants 
are associated with high base-line variation of a mutation rate of ~10
-8
 per base per 
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generation (Genomes Project Consortium et al. 2012). The baseline variation is high 
even if only considering LoF variants. Each individual carries between 60-100 LoF 
variants, from which 20 in homozygous state (Genomes Project Consortium et al. 
2012, MacArthur et al. 2012). Unlike some structural variants, sequence variants 
have low recurrence rate, so that any two individuals are unlikely to harbor exactly 
the same de novo sequence variant. Prior to the emergence of the new sequencing 
technologies, systematic genome-wide analysis of rare sequence variants has been 
impossible. During the past years, genome-wide sequencing studies have focused on 
the exome, hypothesized to tackle the highest rate of functional variants with the 
cost of sequencing. Whole exome sequencing (WES) is used particularly to identify 
rare coding variants that are not tagged by SNP array based GWAS studies (Teer et 
al. 2010). Compared to the sample sizes used in GWAS studies, the sample sizes in 
WES studies have still been small, which is likely to be one of the reasons why these 
studies have not yet reached their full potential in revealing functional variants. 
However, in Mendelian diseases WES studies have already proven to be an efficient 
approach (Kiezun et al. 2012).  
 
2.4 Population structure in genetic studies of complex traits 
A systematic ancestry difference between cases and controls, called population 
stratification, is a well characterized confounder of association analysis. Population 
stratification can easily remain unnoticed in candidate gene studies where only 
handful of SNPs are tested. Ancestry differences between cases and controls in 
GWAS can be detected as inflation of the expected distribution of test statistics and 
be appropriately handled as part of the analysis (Price et al. 2010). Population 
differences, however, can also be used to advantage in genetic studies. Although 
population differences for common variants have proven to be of little benefit in 
genetic studies, the situation for rare variants is different and utilization of special 
populations and consanguineous families has led to the identification of multiple 
causative variants for Mendelian disorders.  
2.4.1 Utilizing founder populations in disease mapping  
A significant reduction in population sizes in genetic terms referred to as a 
population bottleneck, followed by a rapid population growth reduces allelic 
diversity in the founder population and allows genetic drift to act on the remaining 
genetic variants. This leads to the relative enrichment of some alleles at the cost of 
losing others (Figure 7). These genealogical events can have far-reaching 
consequences arising as local difference in disease prevalence and the genetic 
makeup underlying them (Peltonen et al. 2000). Rare variants are more prone to 
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stochastic alteration in their allele frequencies and are thus a major substrate for 
genetic drift in founder populations. 
 
 
Figure 7.  Schematic presentation of a population bottleneck and genetic drift 
shaping the genetic makeup of a founder population. During the bottleneck and the 
following population expansion the genetic diversity of the founder population 
declines and some variants become enriched in the subsequent founder population.  
Population isolates have been useful in identifying genetic causes for rare Mendelian 
diseases, such as the diseases of Finnish disease heritage - a constellation of 36 rare, 
mostly autosomally recessive disorders that are more common in Finland than 
elsewhere in the world (http://www.findis.org/) (Norio et al. 1973, Peltonen et al. 
1999). The isolate design has also been a benefit to the identification of genetic 
variants of more complex traits, such as lactose intolerance, which shows significant 
geographical variation in prevalence likely due to positive selection (Enattah et al. 
2002, Enattah et al. 2007). Other Mendelian variants of complex diseases identified 
in other isolate populations include Hirschsprung disease in the Amish and 
nonsyndromic hearing loss in the Bedouin populations (Puffenberger et al. 1994, 
Scott et al. 1995). One of the most impressive examples of the use of isolate 
populations in genetic studies is from Iceland, where the resourceful use of known 
genealogy, extended pedigrees and detailed medical data has been successfully used 
to identify a plethora of genetic variants to complex traits, such as pigmentation, 
myocardial infarction, T2D, and many others (Helgadottir et al. 2004, Grant et al. 
2006, Sulem et al. 2007). An extreme example of simplistic genetic architecture of 
complex traits in isolate populations is the identification of nonsynonymous 
mutation in Exon 2 of TYRP1 gene. The variant explains 46% of variation in blond 
hair color among Solomon islanders, whereas the mutation is absent in other 
populations (Kenny et al. 2012). A GWAS of amyotrophic lateral sclerosis (ALS), 
carried out in Finland required 10% of the number of familial cases in Finland 
compared to a study conducted in sporadic patients from United Kingdom 
(Laaksovirta et al. 2010, Shatunov et al. 2010). Indeed the success here has been 
mostly driven by the tendency of the affected individuals to carry the same allele 
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and also the relative simplicity in the genetic makeup underlying the traits among 
the specific populations.  
 
2.4.2 Finland: a north eastern isolate in Europe  
Finland has been inhabited since the end of the last glacial age around 10000 years 
ago. During the prehistoric era only a few thousand hunter gatherers lived on the 
Finnish peninsula. According to archeological, linguistic, and genetic evidence there 
was an influx of small immigrant groups mainly from south and east, but also from 
the west during this time, 6000-4000 years ago. Based on studies on Y-chromosome 
lineages, a dual origin of Finns has been hypothesized to result from migration from 
east and south 4000 and 2000 years ago, respectively. However, all migrations can 
be considered to have mixed with the native Finnish population that had been 
inhabiting the area since the continental ice sheet melted (Varilo 1999, Norio 2003).  
 
The founding of the current Finnish population has continued for thousands of years. 
The first inhabitants settled in the coastal region (south and west), consequently 
termed the “early settlement” and for centuries only this part of the land remained 
populated. Starting in the 16
th
 century, the inhabitation of the inland known as the 
“Late Settlement” of Finland began from the South Savo region (Figure 8). At this 
time the population in Finland was 250 000 inhabitants. Both the pressure to 
cultivate more land and political decisions including broadening the country’s 
borders for economic purposes and tax benefits drove the migration movement. By 
the end of the 17
th
 century the inhabited area of Finland had doubled and most of the 
land had become inhabited albeit sparsely. Subsequent genetic isolation of the 
Finnish population followed due to famine and epidemics. During the 1696 and 
1698 period, famine and following epidemics killed one third of the population of 
400 000 at that time. During the last 300 years the Finnish population has grown 
from 250 000 to the 5.5 million inhabitants today (Norio et al. 1973, Varilo 1999, 
Norio 2003). 
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Figure 8. The internal migration from South-Savo (grey shaded area) towards the 
western, central and north of Finland (Teppo Varilo).  
2.4.3 Population genetics of Finland  
Significant effort has been invested into studies of the genetic origins of Finns. The 
uniparentally inherited mitochondrial and Y-chromosomal markers are useful for 
population genetics due to their special modes of inheritance. The Y-chromosome is 
inherited paternally as a haploid chromosome. It undergoes recombination only in 
the telomeric parts, which is why new haplotypes are introduced to it only as a 
consequence of new mutations. Mitochondrial DNA (mtDNA) is inherited 
maternally. It has a higher rate of mutation than autosomes and it does not undergo 
recombination.  
 
The paternally inherited Y-chromosomes show reduced genetic diversity in Finns 
compared to rest of Europe consistent with a tight population bottleneck followed by 
rapid population expansion (Sajantila et al. 1996, Kittles et al. 1998, Lahermo et al. 
1999, Palo et al. 2009). There are two major Y-chromosome lineages among Finns, 
one of eastern and the other of western (Scandinavian) origin (Kittles et al. 1998, 
Lahermo et al. 1999, Lappalainen et al. 2006). Similar reduction in genetic diversity 
is not seen for mtDNA as for Y-chromosome in Finns (Lahermo et al. 1996, 
Sajantila et al. 1996, Hedman et al. 2007, Palo et al. 2009). Earlier, the higher 
mutation rate of mtDNA has been considered to cause these differences between Y-
chromosomal and mtDNA lineages (Sajantila et al. 1996). However, since the 
mitochondrial markers used represent old stable mutations, more likely explanation 
seems to be a more recent male specific gene flow from Scandinavia to the west-
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coast of Finland (Lappalainen et al. 2006, Palo et al. 2009). Overall, both mtDNA 
and Y-chromosomal data suggest European ancestry of the Finnish population. In 
addition, the Y-chromosomal gene pool shows significant similarities with more 
Eastern populations - a tendency that is not shared with the mtDNA, which is 
indistinguishable from other European populations (Sajantila et al. 1995, Lahermo et 
al. 1996, Kittles et al. 1998, Lahermo et al. 1999, Finnila et al. 2001).  
 
The hallmarks of the recent founding bottleneck also manifest in the autosomal 
genetic fingerprint of Finns. In general Finns have longer overall LD compared to 
rest of Europe (Varilo et al. 2003, Service et al. 2006).There is an enrichment of rare 
and low frequency variants in Finland. Moreover, the haplotypes that carry these 
variants are on average longer among Finns than among other European populations, 
all of which is suggestive of a recent shared ancestry among Finns(Genomes Project 
Consortium et al. 2012). The multiple consecutive bottlenecks have resulted in the 
reduction of genetic diversity in Finland compared to the rest of Europe. Despite this 
phenomenom, Finns are not genetically homogenous, but internal migration has also 
caused significant genetic substructure within the country. The genetic variation of 
the Y-chromosome in the Finnish population demonstrates significant east-west 
differences, supporting that there has been a later Scandinavian gene flow to the 
population of Western-Finland, but not into Eastern-Finland (Lappalainen et al. 
2006, Palo et al. 2009). Autosomal SNP allele information also demonstrates clear 
east-west and north-south gradients, as well as regional genetic differences within 
the country (Jakkula et al. 2008). Illustrative of the uniqueness of the genetic 
makeup of Finland is the Finnish disease heritage diseases that are more common in 
Finland than anywhere else in the world. The majority of the diseases are 
autosomally recessive and one major mutation is identified for each of them. 
Depending on the age of the founder mutation, some of the diseases are scattered 
around the country whereas others demonstrate regional clustering of patients 
(Peltonen et al. 1999). Similarly, risk for some more complex disorders, including 
schizophrenia and intellectual disability, varies regionally in Finland following the 
pattern of internal migration (Hovatta et al. 1997, Haukka et al. 2001, Perala et al. 
2008). 
 
2.4.4 The North-Eastern internal isolate of Kuusamo  
Kuusamo is located in the north-eastern border area of Finland. It is the geographical 
region of one of the most studied internal genetic isolates in Finland. The area of 
Kuusamo was inhabited by Finns towards the end of the internal migration wave in 
the 17
th
 century. The first Finnish settler moved to Kuusamo in 1676 and was 
followed by 34 families of 194 individuals mainly from Ostrobothnia and South 
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Kainuu in 1685. The populations of both regions had previously descended from 
earlier migration from South Savo. Up to 60 to 70 families lived in Kuusamo by 
1687 and during the great famine in 1696-1698 half of the Finnish population and 
nearly all of the native Saami inhabitants died. Since then the Saami people have 
gradually disappeared by emigration and by assimilation into the agricultural 
Finnish population. In 1718, 615 individuals inhabited Kuusamo. The population 
grew rapidly and reached 2000 individuals in 1760 and it had further doubled by 
1842, it eventually reached 10 000 individuals by 1910. The current population of 
Kuusamo is roughly 16 000 inhabitants. The population of Kuusamo remained 
almost completely genetically isolated until the Second World War (Varilo 1999). 
Consistent with its population history, Kuusamo demonstrates even longer LD 
compared to other regions of Finland (Varilo et al. 2000, Jakkula et al. 2008). The 
recent genealogical history of Kuusamo (Figure 9) is such that the majority of 
patients with schizophrenia in that region are part of one extended pedigree (Hovatta 
et al. 1997, Hovatta et al. 1999). 
 
 
Figure 9. Extended pedigrees in the internal isolate of Kuusamo links 
schizophrenia patients in the modern population (Courtesy of Teppo Varilo).  
 
2.5 Genetic architecture of schizophrenia and related mental 
disorders 
Both common and rare genetic variants contribute to the genetic risk of 
schizophrenia (Figure 10). Schizophrenia has been demonstrated to have an 
indisputable polygenic component that consists mostly of common low impact 
variants that make up the majority of the population genetic risk (Purcell et al. 2009, 
Ripke et al. 2013). In addition to common variants, rare high impact variants are 
also important in the etiology of schizophrenia. Although the rare variants have low 
attributable risk at the population level, individually they can confer substantial 
risks. Suggested already by epidemiological studies, the genetic evidence strongly 
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supports shared genetic risk across psychiatric and developmental disorders, 
suggesting common biological grounds for these diagnostically different disease 
entities (Sullivan et al. 2012).  
 
 
Figure 10. The allelic spectrum of schizophrenia. Chromosomal deletions shown in 
red, duplications in blue and SNPs in grey. The x-axis the log10 allele frequency and 
y-axis is the log10 of the Odds Ratio (OR). The values are taken from.(Stefansson et 
al. 2008, Ingason et al. 2011, Levinson et al. 2011, Ripke et al. 2011, Malhotra et al. 
2012, Guha et al. 2013, Ripke et al. 2013) 
2.5.1 Common genetic variants in schizophrenia  
Schizophrenia is a highly polygenic disorder, with thousands of genetic variants 
contributing to the risk, each variant having only minor effects (Purcell et al. 2009, 
Ripke et al. 2013). The cumulative common genetic variation is estimated to 
account for over 30% of the variance in the liability (Ripke et al. 2013). However, 
the majority of the risk accounted for by genetic variants still remains to be assigned 
to specific gene variants. 
 
As in the case of many other complex diseases, genetic studies that used family 
based linkage and candidate gene approaches were largely unsuccessful in 
identifying gene variants underlying schizophrenia (Lewis et al. 2003, Allen et al. 
2008, Ng et al. 2009). In a meta-analysis of over 1000 independent association 
studies in schizophrenia, 16 genes (APOE, COMT, DAO, DRD1, DRD2, DRD4, 
DTNBP1, GABRB2, GRIN2B, HP, IL1B, MTHFR, PLXNA2, SLC6A4, TP53, TPH1) 
showed suggestive evidence of association with average odds ratio of 1.23 (Allen et 
al. 2008). Of these 16 genes, DRD2 is the main target for antipsychotic medication 
and has been confirmed to convey a risk for schizophrenia in a recent large scale 
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GWAS study. (Schizophrenia Working Group of the Psychiatric Genomics 2014). 
The genetic risk for schizophrenia started to emerge with the advent of SNP array 
technology and large scale case-control GWAS studies. The first GWAS studies 
were published in 2009 and revealed a substantial association with the MHC region 
on chromosome 6 (Purcell et al. 2009, Shi et al. 2009, Stefansson et al. 2009). These 
studies were followed by two larger meta-analyses with the latter combining 13 833 
cases and 18 310 controls and identified 22 distinct loci for schizophrenia. Of these, 
13 associations were novel and nine had reached genome-wide significance in 
previous studies (Purcell et al. 2009, Shi et al. 2009, Stefansson et al. 2009, Ripke et 
al. 2011). Of the 22 associated loci, six (6p21.333-p21.32, 1p31.1, 5q33.1-q33.2, 
2q22.3, 2q33.1, 3p22.2) overlapped with regions that had previously been reported 
to show nominal evidence for linkage (Lewis et al. 2003, Ng et al. 2009). However, 
the linkage regions spanned tens of megabases and the statistical evidence has been 
at best only suggestive, thus the evidence prior GWAS for these regions and 
schizophrenia were inconclusive to say the least. In addition, none of the assigned 
probable candidate genes in the 22 regions had been implicated in schizophrenia in 
candidate gene studies prior to December 2011 (http://www.szgene.org/) with the 
exception of CACNAC1 (Green et al. 2010, Nyegaard et al. 2010). CACNAC1 was 
initially implicated in bipolar disorder (Sklar et al. 2008), which also triggered its 
study in other psychiatric disorders including schizophrenia and depression (Green 
et al. 2010, Nyegaard et al. 2010). Previously, suggestive association between 
ZNF804A, located several hundred kb distal to 2q32.1, and schizophrenia, cognitive 
performance in schizophrenia paitents, in addition to bipolar disorder had also been 
reported (O'Donovan et al. 2008, Riley et al. 2010, Steinberg et al. 2011). Several 
studies have also provided suggestive evidence for TCF4 on 18q21.2 and NRGN, 
located 700 kb away from the GWAS association on 11q24.2, for schizophrenia 
prior to the latest GWAS studies (Ruano et al. 2008, Stefansson et al. 2009, Li et al. 
2010).  
 
The largest GWAS conducted for schizophrenia to date included 37 000 cases and 
113 000 controls and revealed 128 distinct associations in 108 genetic loci for 
schizophrenia: 83 of which were novel. The large number of associations enabled 
for the first time convincingly to speculate the biological pathways involved in the 
etiology of schizophrenia. First, the association is not randomly distributed across 
genes, but is enriched in those genes that are expressed in the brain and neurons, 
particularly those of the cortical and striatal neuronal lineages, in addition to 
immunological genes. Moreover, these associations included genes related to 
dopaminergic and glutaminergic neurotransmission and synaptic plasticity, systems 
that had previously been implicated in schizophrenia by pharmacological studies. 
The latest GWAS results are consistent with and extend the previous GWAS 
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findings of genes encoding for voltage gated calcium channel subunit. As with other 
complex traits, the major associations do not seem to affect amino-acid sequences 
encoded by the genes but rather highlight regulatory mechanisms. The multiple loci 
included gene variants with regulatory roles in gene expression, as defined by the 
expression quantitative trait loci (eQTL) and enhancers that are active in the brain 
and in tissues with immune functions (Schizophrenia Working Group of the 
Psychiatric Genomics 2014). 
 
2.5.2 Rare and de novo sequence variants in schizophrenia 
Similar to that found for common variants, the cumulative polygenic burden of rare 
variants (i.e. variants with allele frequency of < 0.0001) influences the genetic 
susceptibility to schizophrenia. The contribution of the rare variants to schizophrenia 
remains, however, still smaller on a population level compared to the susceptibility 
explained by common genetic variants (Purcell et al. 2014). Although the studies of 
rare sequence variants in schizophrenia have not unequivocally pinpointed specific 
risk variants, a burden of rare variants in functional gene groups including voltage 
gated calcium ion channels, activity regulated cytoskeleton associated scaffold 
protein (ARC) of postsynaptic density, and targets of Fragile X Mental Retardation 
Protein (FMRP) are enriched with rare disruptive mutations in schizophrenia 
patients (Purcell et al. 2014). Moreover, the schizophrenia GWAS results overlap 
with rare CNVs and de novo nonsynonymous mutations that have been identified in 
schizophrenia, autism, and intellectual disability (Schizophrenia Working Group of 
the Psychiatric Genomics 2014). 
 
The hypothesis of significant impact of rare variants in mental disorders is well 
justified. Epidemiological studies suggest increased mortality and reduced fecundity 
in severe mental disorders that raise an evolutionary paradox of a heritable genetic 
predisposition for the disorders (Nordentoft et al. 2013, Power et al. 2013). Despite 
high heritability estimates, a significant portion of schizophrenia patients are 
sporadic and do not have a family history of mental disorders (Mortensen et al. 
1999). The correlation of paternal age with risks for mental disorders (D'Onofrio et 
al. 2014, McGrath et al. 2014), and increased mutation rates (Kong et al. 2012), in 
addition to the importance of recurrent and de novo mutations in early onset mental 
disorders (autism and intellectual disability) gave rise to the de novo hypothesis in 
mental disorders. De novo mutations seem especially important in severe intellectual 
disability, where patients constantly show higher rates of de novo LoF mutations 
compared to controls and these mutations cluster in known intellectual disability 
causing genes (Vissers et al. 2010, Rauch et al. 2012, Gilissen et al. 2014). In 
addition, the somewhat disappointing results obtained from the first GWAS studies 
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on schizophrenia led to even more enthusiasm for the hypothesis of the importance 
of rare variants in the etiology of schizophrenia.  
 
Indeed, some studies have reported elevated mutation rates in schizophrenia 
(2.59×10
-8
 per nucleotide per generation) (Girard et al. 2011) and in autism 
(2.17×10
-8 
per nucleotide per generation) (O'Roak et al. 2012). However, 
collectively, de novo sequence variants seem less significant for schizophrenia 
compared to that of intellectual disability or even autism (Fromer et al. 2014). 
Patients with schizophrenia have been reported to have slightly more 
nonsynonymous mutations compared to controls. This enrichment has been reported 
to be biased towards fetal expressed genes that are also found to carry excess de 
novo mutation in autism (Xu et al. 2011, Xu et al. 2012). These findings are not, 
however, supported across all studies (Fromer et al. 2014). The strongest impact of 
de novo LoF mutations seems to be among schizophrenia patients with poor school 
performance (Fromer et al. 2014). The de novo nonsynonymous mutations are 
enriched in synaptic genes, specifically in genes associated with N-methyl-D-
aspartate receptor (NMDAR) complex and the ARC complex. In addition, FMRP 
targets are reported to be enriched for de novo nonsynonymous mutations (Fromer et 
al. 2014).  
 
The analysis of rare variants is statistically challenging due to their rarity which puts 
severe limitations on statistical power. The sample sizes of current sequencing 
studies have been one-tenth to one-hundredth compared to those of GWAS (and 
CNV studies). The human genome has a high background rate of rare variation with 
a mutation rate of 10
-8 
per nucleotide per generation, corresponding to over 60 new 
mutations. This would translate into on average 0.86 amino-acid altering mutations 
per generation in the general population (Lynch 2010). Even variations that are 
predicted to be protein disruptive are abundant in the general “healthy” population 
(MacArthur et al. 2012). This is reflected in the inability to identify specific rare 
sequence variants at an appropriate statistical threshold. The largest study of de novo 
mutations in schizophrenia to date (623 trios) reported two de novo LoF mutations 
in the gene that encodes for TAF13, suggesting this as a candidate gene for 
schizophrenia (Fromer et al. 2014).  
 
Patients with autism seem to have more potentially disruptive de novo 
nonsynonymous mutations similarly to schizophrenia patients (Iossifov et al. 2012, 
Neale et al. 2012, Sanders et al. 2012). Recurrent mutations for autism in CHD8, 
KATNAL2 and SCN2A identified in WES studies suggest these genes are genuine 
risk genes for autism (Neale et al. 2012, O'Roak et al. 2012, Sanders et al. 2012). 
Emerging evidence for the enrichment of disruptive de novo mutations support the 
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role of brain expressed, synaptic genes and FMRP target mRNAs in autism (Iossifov 
et al. 2012, Neale et al. 2012, O'Roak et al. 2012, Sanders et al. 2012). Furthermore, 
among autism patients rare mutations in genes related to NMDAR complex, 
including SHANK2, SYNGAP1, and DLGAP2, or mutations in SHANK3, NLGN3, 
and NLGN4X, indicate shared biological pathways between autism and 
schizophrenia (Jamain et al. 2003, Durand et al. 2007, Berkel et al. 2010, Pinto et al. 
2010). 
 
2.5.3 Rare CNVs in schizophrenia 
Structural variation has long been acknowledged as a risk factor for psychiatric 
illnesses including schizophrenia. Even to date, one of the highest known singular 
risk factors for schizophrenia is the VCFS, which was described over 20 years ago. 
Approximately one-third of VCFS patients develop a psychotic disorder and over 
20% fulfill diagnostic criteria for schizophrenia (Pulver et al. 1994, Murphy et al. 
1999). The systematic genome-wide assessment of microscopic and submicroscopic 
CNVs has become possible with the development of array based methods involving 
both comparative genomic hybridization (CGH) and oligonucleotide SNP arrays 
(Pinkel et al. 1998, Bignell et al. 2004). Both methods were used early on for studies 
on intellectual disability and autism due to the strong a priori hypothesis of the 
prominent role of CNVs in these conditions (Vissers et al. 2003, Friedman et al. 
2006, Marshall et al. 2008). Cumulative evidence from the first CNV scans in 
schizophrenia suggested that there is an increased burden of rare (<1%) large CNVs 
in schizophrenia, although the magnitudes varied extensively depending on the 
study (International Schizophrenia Consortium 2008, Walsh et al. 2008, Xu et al. 
2008, Kirov et al. 2009). Although these studies indicated a handful of individual 
plausible risk CNVs including deletions on 22q11.2, and NRXN1, they were unable 
to provide required statistical evidence for involvement of specific variants. Only 
two of the first phase CNV scans, including that carried out in study I of this thesis, 
had the statistical power to identify individual risk deletions at 1p21.2, 15q11.2, 
15q11.3, and 22q11.2 with confidence (International Schizophrenia Consortium 
2008, Stefansson et al. 2008). 
 
To date, at least 15 CNVs have been repeatedly associated with increased risk for 
schizophrenia by independent studies in different populations. The CNVs include 
roughly equal number of duplications and deletions (Table 2). Combined, over 2.5% 
of schizophrenia patients carry these CNVs though their frequency in controls is 
only around 0.5% (Stefansson et al. 2008, Ingason et al. 2011, Levinson et al. 2011, 
Malhotra et al. 2012, Guha et al. 2013). As a consequence of the reduced fecundity 
associated with severe mental disorders including schizophrenia, CNVs associated 
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with large effect sizes are expected to rapidly disappear from the population. 
Accordingly, especially the sporadic cases of both schizophrenia and autism have an 
elevated rate of de novo CNVs and many of the reported CNVs represent de novo 
mutations from recurrent CNV events (Sebat et al. 2007, Stefansson et al. 2008, Xu 
et al. 2008, Kirov et al. 2012). Overall, the mutation rate for the CNVs associated 
with schizophrenia is high affecting one in a few thousand to one in several tens of 
thousands individuals. However, negative selection pressure operates on the 
recurrent CNVs in such a way that following the mutation event each mutation 
exists only for only a few generations in the population (Rees et al. 2011). 
 
Besides the large sample sizes, the analysis of rare large-scale CNVs has benefitted 
from the low background rate of large scale structural variation in general 
populations. In general populations 11% of individuals are reported to carry >500kb 
CNVs (Pietilainen et al. 2011). The variations that have been identified in 
schizophrenia have been associated with very high risks (OR: 2.5-60.0) and they 
have been mostly recurrent with biased mutation events in specific regions of the 
genome. This has enabled multiple replications of the findings across populations in 
sample sets of tens of thousands individuals (Levinson et al. 2011, Malhotra et al. 
2012, Kirov et al. 2014). For rare sequence variations, similar recurrence for a single 
mutation at a given site is less probable. Much more variation is expected for 
sequence variants compared to large CNVs as basically any of the 6.5 billion bases 
can mutate. Even if the microhomology of the breakpoint were to vary from 
individual to individual, the main chunk of the CNV remains usually the same. 
 
As with de novo sequence variants, schizophrenia linked CNVs are enriched with 
genes encoding for postsynaptic proteins and genes related to postsynaptic density. 
Specifically NMDAR and ARC postsynaptic signaling complexes are enriched 
among the CNVs associated with schizophrenia. These complexes are important for 
synaptic plasticity and in cognition, and their functions are also now linked to 
schizophrenia (Kirov et al. 2012). 
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Table 2. Rare CNVs associated with schizophrenia  
Locus type start (Mb) end (Mb) genes OR Association to Aut/ID  Assocaition to BPD OMIM # 
 1q21 del 146.57 147.39 multiple 8.1 yes 
 
612474 
1q21 dup 146.57 147.39 multiple 4.2 yes yes 612475 
2p16.3 del 50.14 51.26 NRXN1 7.5 yes 
 
614332 
3q29 del 195.73 197.34 multiple 63.0 yes yes 609425 
7q11.23 dup 72.74 74.14 multiple 7.5 yes 
 
609757 
7q36.3 dup 158.8 158.9 VIPR2 2.1 yes 
 
613959 
15q11.2 del 22.8 23.09 multiple 2.73 yes 
 
615656 
15q11.2-13.1 dup 20.8 26.2 multiple 5.1 yes 
 
176270 
15q13.3 del 30.9 33.5 multiple 10.7 yes 
 
612001 
16p13.11  dup 15.4 16.3 multiple 2 yes 
 
na 
16p11.2  distal del 28.82 29.05 multiple 6.25 yes 
 
611913 
16p11.2  dup 29.5 30.2 multiple 9.4 yes yes 614671 
17q12 del del 34.81 36.2 multiple 9.5 yes 
 
614527 
17p12/HNPP del 14.0 15.4 multiple 5.7 no 
 
162500 
22q11.21 del 18.7 21.8 multiple 15.21 yes yes 192430 
 Source: (Stefansson et al. 2008, Levinson et al. 2011, Malhotra et al. 2012, Guha et al. 2013) 
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Since most of the CNVs associated with schizophrenia are large and span multiple 
genes, it is difficult to make a clear inference about the pathological mechanism 
related to them. The clearest exception here is the 2p16.3 deletion that involves only 
the NRXN1gene (Kirov et al. 2008, Rujescu et al. 2008, Walsh et al. 2008). The 
NRXN1 protein is a synaptic cell adhesion molecule that is found presynaptically. It 
is thought to interact with postsynaptic neuroligin together with other NRXNs to 
connect presynaptic and postsynaptic neurons at synapses in excitatory and 
inhibitory neurons (Sudhof 2008). Deletions and disruptive sequence variants in 
NRXN1 have also been linked with autism and intellectual disability (Feng et al. 
2006, Friedman et al. 2006, Autism Genome Project et al. 2007, Kim et al. 2008, 
Marshall et al. 2008). In addition, mutations in genes encoding for neuroligins are 
associated with autism (Thomas et al. 1999, Jamain et al. 2003). Another example 
of a single gene involving CNV is the duplication in 7q36.3 that involves the VIPR2 
gene (Vacic et al. 2011). VIPR2 encodes for vasoactive intestinal peptide receptor 
that serves as a neuropeptide receptor. It is a widely expressed G-coupled receptor 
that is believed to have a role in regulating synaptic transmission (Cunha-Reis et al. 
2005, Yang et al. 2009).  
 
The mechanisms leading to pleiotropic effects observed in genetic mutations 
associated with mental disorders are yet to be discovered. For example mutations in 
neuronal adhesion molecules neurexins and neuroligins are linked with 
schizophrenia, autism, Tourette’s syndrome and learning disability and the 
phenotypes can vary even within families. It may be the case that cognitive diseases, 
including schizophrenia, arise from subtle changes in a subset of synapses in a 
neural circuit in comparison with general impairment of all synapses in all circuits. 
A consequence of this would be that the same molecular alteration could produce 
different circuit changes, which would result in different ranges of neurological 
symptoms that are then classified as different disorders (Sudhof 2008). To date no 
monogenic form of schizophrenia has been identified (Sullivan 2012). Even the rare 
high penetrant variations identified in schizophrenia are associated with variable 
phenotype and are usually more strongly associated with cognitive performance, 
autism, and intellectual disability (Kirov et al. 2014, Stefansson et al. 2014). Severe 
disrupting mutations in genes such as CACNA1C and TCF4 with common variation 
linked with schizophrenia do not actually cause schizophrenia, but instead 
syndromes such as Timothy syndrome and Pitt-Hopkins syndrome, respectively 
(Splawski et al. 2004, Amiel et al. 2007). 
 
The genetic evidence for schizophrenia clearly supports a highly polygenic model 
for schizophrenia. It may be that the risk for schizophrenia would be mediated 
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through a pathway rather than direct aggregation of risk variants (Sullivan 2012). 
This hypothesis is supported by 1) the evident polygenicity of the disorder; 2) the 
emerging evidence from genetic studies that suggest the existence of specific 
pathways, such as MIR-137 regulated network; and 3) the lack of evidence for 
Mendelian forms of schizophrenia. Most high impact variants associated with 
schizophrenia are associated with a heterogeneous phenotype, with a cognitive 
domain being the main driver of the associations. Moreover, severe protein 
destroying mutations in genes, for which common variants are associated with 
schizophrenia do not result in a schizophrenia diagnosis but rather in intellectual 
disability. For many other complex diseases such as Alzheimer’s or T2D, Mendelian 
forms exist (Sullivan 2012). 
 
2.5.4 Genetic sharing across mental disorder groups  
Epidemiological analyses of family, adoption, and twin studies suggest that the 
diagnostically distinct mental disorders, such as bipolar disorder, major depressive 
disorder, autism, and intellectual disability to co-exist in same families (Mortensen 
et al. 2009). Since these psychiatric illnesses are highly heritable, this coexistence is 
thought to be at least partially due to shared genetic risk factors. The evidence for a 
shared genetic component is particularly strong for schizophrenia and bipolar 
disorder. These two disorders have a high genetic correlation as estimated by 
common SNPs (68%) and occurrence within families (63%) (Lichtenstein et al. 
2009, Purcell et al. 2009, Cross-Disorder Group of the Psychiatric Genomics et al. 
2013). Moreover, this genetic risk has started to unfold with the discovery of 
specific gene variants such as the individual and combined associations with 
CACNAC1, NCAN, ANK3, DGKH, ITIH3-ITIH4 for both schizophrenia and bipolar 
disorder (Ferreira et al. 2008, Sklar et al. 2008, Cichon et al. 2011, Psychiatric 2011, 
Ripke et al. 2011, Zeng et al. 2011, Muhleisen et al. 2012, Ripke et al. 2013). 
CACNAC1 is also independently associated with major depressive disorder (Green 
et al. 2010). A significant genetic correlation calculated from common SNPs exists 
also between schizophrenia and major depressive disorder (43%) and between 
autism spectrum disorders (16%), as well as between bipolar disorder and major 
depressive disorder (47%), and ADHD and major depressive disorder (32%) (Cross-
Disorder Group of the Psychiatric Genomics et al. 2013). A combined association 
analysis with the five disorders revealed shared genomic loci that probably involve 
genes encoding for ITIH3, AS3MT, CACNAC1, and CACNB2, suggesting that some 
of the independent associations seen previously for schizophrenia are also shared 
with the other disorders (Cross-Disorder Group of the Psychiatric Genomics et al. 
2013). The sharing of rare variants across diagnostic boundaries seems to be more 
common in schizophrenia and the early onset disorders according to evidence 
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obtained from structural, and de novo sequence variants (Cooper et al. 2011, 
Malhotra et al. 2012, Xu et al. 2012, Fromer et al. 2014, Kirov et al. 2014). Rare 
sequence variants, include functional entities that are seen also in studies of de novo 
variants, CNVs, and common variants (Purcell et al. 2014). 
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3 Aims of the study 
The aim of this thesis was to investigate the role of large scale CNVs in 
schizophrenia and other related neurodevelopmental traits. The aim was to 
illuminate the genetic relationship between disorders that are traditionally 
considered different entities. We focused on rare CNVs, with particular emphasis on 
large scale deletions for three reasons. First, at the time of conducting these studies it 
was feasible to identify such variants in the existing genotype data obtained from 
genome-wide association studies that had been conducted in schizophrenia case-
control samples and in Finnish population and family cohorts. Second, large 
genomic variations, particularly deletions, are predicted to have substantial effect on 
phenotypes. It was therefore plausible to detect association with the data sets 
available for the studies. Third, the rare disruptive mutations fit the evolutionary 
paradigm of severe mental disorders there being a role of recurrent structural 
variation to developmental disorders that has been known for decades.  
 
The specific aims of this study were  
 
I. To investigate if large recurrent deletions predispose to schizophrenia  
(Study I). 
 
II. To study the global impact of large (>500 kb) CNVs on a population 
level for seven traits hypothesized to reflect abnormal neuronal 
development (Study II). 
 
III. To utilize young population isolate in identifying ancestral genomic 
deletions that would predispose to schizophrenia and related 
neurodevelopmental phenotypes (Study III). 
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4 Materials and methods 
4.1 Study subjects 
The Finnish schizophrenia patients were identified from a Finnish nationwide study 
sample of families with schizophrenia, from birth cohorts and from population-
based health surveys. Finnish population and control samples were ascertained from 
nationwide collections, including participants to prospective birth cohorts and 
population-based health surveys. The cohorts have detailed clinical phenotype 
information collected from Hospital Discharge Register, questionnaires, and clinical 
examinations available. The clinical data were utilized in studies II and III. The 
international samples included schizophrenia patients and controls combined in the 
international schizophrenia consortia, including, SGENE (Stefansson et al. 2009), 
the International Schizophrenia Consortium (ISC) (Stone et al. 2008), and the 
Swedish Schizophrenia Consortium (SSC) (Bergen et al. 2012). All of the 
multicenter studies have been reviewed and approved by their respective appropriate 
local ethical committees and all participants had signed a written informed consent. 
The study subjects and the GWAS arrays used are listed in table 4 in the method 
section. 
 
4.1.1 Finnish study samples  
FINNISH SCHIZOPHRENIA FAMILY SAMPLE (FSFS) 
Individuals from the FSFS were included in studies I and III. The schizophrenia 
family sample collection was initiated in 1988 by the National Public Health 
Institute (since 2009 the National Institute for Health and Welfare (THL)). Three 
national registers: the Hospital Discharge Register, the Pension Register, and the 
Populations Register were used to identify all individuals born between 1940 and 
1976, and who had been hospitalized, had received disability pension, or had been 
granted entitlement to free out-patient antipsychotic medication for the treatment of 
schizophrenia between 1969-1998 according to the International Classification of 
Diseases ICD-8, ICD-10, and DSM-III-R. (N=33,731 individuals) (Wegelius et al. 
2013). First degree relatives (i.e. parents, siblings, and offspring) of patients were 
identified through the Population Register Centre and pedigrees of the families were 
constructed based on this information (Figure 11) (Hovatta et al. 1997). Information 
of psychiatric morbidity and diagnoses for the family members was obtained 
through the health care registers. 
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Probands were contacted by their treating physician and additional family members 
were contacted only upon approval by the proband. In general, families with at least 
two affected individuals were contacted. However, families that originated from the 
internal isolate that had a high risk for schizophrenia, also families with one affected 
individual were contacted. Clinical data were collected from all mental health 
treatment contacts. 
 
A DSM-IV lifetime diagnosis of each patient was assigned independently by two 
psychiatrists based on the patient’s medical records from all lifetime in- and 
outpatient psychiatric treatment contacts, completed by information from the clinical 
interview when available. In the case of discrepancy of diagnosis, a third psychiatrist 
was consulted and a best estimate for life time diagnosis was assigned. In general 
the concordance between the psychiatrist was high (>95%) (Paunio et al. 2001, 
Tuulio-Henriksson et al. 2002). The Operational Criteria Checklist (OPCRIT) was 
also completed for the affected individuals (McGuffin et al. 1991). All patients with 
a subset of 929 family members (340 affected with schizophrenia or schizoaffective 
disorder) had been interviewed using the Structured Clinical Interview for DSM-IV 
(SCID-I and SCID II) (First et al. 1997) and have been tested using a comprehensive 
neuropsychological test battery (Tuulio-Henriksson et al. 2002). The test battery 
included measures from the Wechsler Memory Scale-Revised (WMS-R) (Wechsler 
1987), the California Verbal Learning Test (CVLT) (Delis et al. 1987), Wechsler 
Adult Intelligence Scale-Revised (WAIS-R) (Wechsler 1981) and covers the central 
cognitive functions impaired in schizophrenia (Heinrichs et al. 1998). In addition, 
the interview included the Scale for Assessment of Positive Symptoms (SAPS) 
(Andreasen 1984) and the Scale for the Assessment of Negative Symptoms (SANS) 
(Andreasen 1983). 
 
DNA samples were collected from 2868 study participants in 670 families (N=983 
patients with schizophrenia or schizoaffective disorder). One index case for 
schizophrenia or schizoaffective disorder from each family was selected for 
genome-wide association study (GWAS) on two occasions. A set of 191 patients 
were included in an international EU-funded consortium called the SGENE 
(www.sgene.eu, Study I, and III). Here individuals with a neurocognitive test data 
available and a subset of the schizophrenia family collection originating from the 
internal north eastern isolate of Kuusamo with approximately three-fold lifetime risk 
of schizophrenia were prioritized. An index case from each of the remaining families 
(N=375) were genotyped genome-wide in study III. Of the 566 patients that were 
included in study III, 171 originated from the internal isolate of Kuusamo.  
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The rest of the Finnish schizophrenia patients (N=86) were identified among the 
participants of the Health 2000 nationwide health survey (H2000) (Perala et al. 
2007) and Northern Finland 1966 Birth Cohort (NFBC 1966) (Moilanen et al. 
2003). These patients had been diagnosed with DSM III-R and DSM IV 
schizophrenia or schizoaffective disorder by using multiple sources of information, 
including structured clinical interviews with SCID-I and medical records. The 
cohorts are described in more detail below. 
 
 
Figure 11. Collection scheme of the schizophrenia family sample. 
THE NORTHERN FINLAND 1966 AND 1986 BIRTH COHORTS (NFBC 1966 
AND 1986) 
All individuals born in 1966 in the two most Northern provinces of Finland were 
recruited to participate in an unselected geographically based prospective birth 
cohort called the Northern Finland 1966 Birth Cohort (NFBC 1966, N=12 058) 
(Rantakallio 1988). The cohort began with the recording of gestational information 
from pregnant mothers and continued with follow ups at birth, at one year old, at 14 
years, at 31 years, and the currently ongoing 46 years old follow up (Sovio et al. 
2007) (http://www.oulu.fi/nfbc/). The follow ups include clinical examinations, 
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questionnaires and information obtained from official registers, combined in a 
detailed phenotype database of the cohort participants. During the last follow-up 
also DNA samples were collected from a representative subset of the cohort that was 
included in studies II and III (N=4932).  
 
Seven phenotypes recorded in NFCB 1966, postulated to relate to central nervous 
system development, were utilized in studies II and III. They were cognitive defect 
(IQ<85), a standardized measure of poor school performance, psychosis, epilepsy, 
neonatal seizures, cerebral palsy/perinatal brain damage, and impaired hearing 
(Table 3). The sample included 59 schizophrenia patients (DSM-III-R) that were 
included as cases for the association analysis of schizophrenia in study II. The rest 
of the cohort (N=488) were used as controls. Study III utilized the division between 
the Kuusamo isolate and rest of Finland. Of the NFBC 1966, 450 individuals (13 
schizophrenia patients) originated from the isolate.  
 
A sample set of 212 individuals included as controls from the internal isolate of 
Kuusamo in study III were ascertained from the NFBC 1986. As with the NFBC 
1966 cohort, NFBC 1986 is a representative prospective birth cohort of all 
individuals born 20 years later in the same geographical region (Jarvelin et al. 
1997). The NFBC 1986 cohort was founded on 9340 live born children that have 
been prospectively followed up since the 12
th
 gestational week. The last follow-up to 
date at age 16 years (years 2001-2002) included 6645 individuals who gave consent 
to participate in the study (Jarvelin et al. 1993, Jaaskelainen et al. 2005). Individuals 
with grandparents originating from the isolate were included in study III. 
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Table 3. Seven Neurodevelopmental phenotypes recorded for NFBC 1966 
included in studies II and III. 
IQ < 85 (Rantakallio et al. 1985) 
 Questionnaire filled in by the midwife at birth 
 questionnaire administered for all children admitted to a children's hospital 
during the first 28 days of life 
 diagnoses on admission to a children's hospital during 1966–1972 
 a questionnaire given to parents when the child was 1 year old, relating to his or 
her health and development 
 hospital records and special forms for children who visited neurological 
outpatient clinics required because of their symptoms.  
 all existing protocols for IQ tests and psychologist's evaluations from child 
guidance centers, hospitals and institutions for mentally retarded children, 
information from national registers of death certificates, hospital discharge 
registers and child subsidies for chronically sick and mentally retarded children 
Repeated grades in school (Isohanni et al. 1998) 
 Questionnaire at the age of 14 years from the participants 
Psychosis (Moilanen et al. 2003) 
 DSM-III-R 
Epilepsy (Lofgren et al. 2009) 
 Hospital Discharge Register 1966-2004 
 Social Insurance Institution of Finland 1966-2004 
Neonatal Seizures and Cerebral Palsy/Perinatal Brain Damage 
(von Wendt et al. 1985, Jarvelin et al. 1997, Jones et al. 1998) 
 Hospital Discharge Register 
 Hospital charts 
Impaired hearing (Sorri et al. 1985, Jarvelin et al. 1997) 
 Air-conduction pure tone thresholds exceeded 20 dB at any of the frequencies 
of 0.25, 0.5, 1, 2, 3, 4, 6, 8 kHz 
 
 
HELSINKI BIRTH COHORT STUDY  
Helsinki Birth Cohort study (HBCS) was used as a whole Finland population sample 
for study III (N=1586) (Eriksson et al. 2001, Barker et al. 2005). The cohort 
includes 8760 individuals born in Helsinki Central Hospital between 1934 and 1944. 
The participants had attended the child welfare clinics in Helsinki and were resident 
in Finland in 1971 when a unique personal identification number was allocated to 
each resident living in Finland including every member of Finnish population 
(Eriksson et al. 2001). A subset of the cohort (N=2003) participated in a clinical 
study between 2001 and 2004 that also involved collection of DNA samples from 
the participants (Barker et al. 2005).  
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THE HEALTH 2000 SURVEY (H2000) 
A total of 2 402 individuals were ascertained on two occasions from a nationally 
representative cross-sectional health survey called the Health 2000 survey and were 
included in studies I and III (Aromaa et al. 2004, Pirkola et al. 2005). The H2000 
health survey,designed to give information on health of the Finnish population, was 
carried out in 2000 and 2001. It included a nationwide representative sample of 8028 
individuals. A subset of 200 individuals was included as the Finnish control sample 
set in a large European schizophrenia consortium called the SGENE (study I) 
(Stefansson et al. 2008). The 200 individuals were matched with Finnish 
schizophrenia cases with regard to sex, age (± 5 years) and place of birth, excluding 
persons with a lifetime history of any psychotic disorders. Persons who had 
participated in a sub-study in which neuropsychological testing had been conducted 
were prioritized (Perala et al. 2007), as well as participants from the high risk 
isolate. The majority of the H2000 participants used in study III (N=2212) were part 
of a sub-study of H2000 that investigated genetic risk factors for metabolic 
syndrome. All individuals with International Diabetes Federation (IDF) definition of 
metabolic syndrome were identified from H2000 and matched controls were 
selected for those individuals (Pajunen et al. 2010, Kristiansson et al. 2012). From 
these individuals, 27 met the DSM-IV diagnosis for schizophrenia or schizoaffective 
disorder, diagnosed in a sub-study focusing on psychotic disorders (Perala et al. 
2007), and were included as cases in study III.  
 
THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY (YFS) 
The Cardiovascular Risk in Young Finns Study (YFS) is a follow-up study of 
cardiovascular risk factors from childhood to adulthood 
(http://youngfinnsstudy.utu.fi/). The study participants were randomly chosen from 
the Population Register and recruited from five university cities in Finland. The 
baseline study was launched in 1980 and included 3596 individuals. Follow-ups 
have taken place on average every three years with the last one to date being in 2007 
at 30 years old. DNA was extracted from the study participants in 2001(Raitakari et 
al. 2003, Raitakari et al. 2008, Smith et al. 2010). The YFS individuals were 
included as controls in study III and included 2308 individuals from YFS with 
GWAS data available. 
 
THE NATIONAL FINRISK HEALTH STUDY (FINRISK) 
Participants of two population cohorts were selected to investigate the enrichment of 
rare deletions between two geographical regions in Finland of differing 
schizophrenia prevalence. All individuals who had both parents originating from the 
internal north-eastern isolate with a high relative risk for schizophrenia were 
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selected among the voluntary participants of a nationwide health cohort Finrisk 
(http://www.thl.fi/fi/tutkimus-ja-asiantuntijatyo/vaestotutkimukset/finriski-
tutkimus/the-national-finrisk-study). The Finrisk cohort is a national survey on risk 
factors of chronic and non-communicable diseases in Finland. The survey has been 
conducted every five years since year 1972 using randomly selected, representative 
population samples from different parts of the country (Vartiainen et al. 2010). The 
173 individuals from the isolate, included in the present study, were selected from 
among the participants of Finrisk surveys 1997 to 2007 (Vartiainen et al. 2010). A 
subset of individuals, aged between 25 and 74, from the Finrisk 2007 health survey 
participated a sub study called Dietary, Lifestyle and Genetic determinants of 
Obesity and Metabolic syndrome in the Helsinki region (Dilgom) (Inouye et al. 
2010). The present study included 612 individuals from Dilgom who were treated as 
population controls.  
 
FINNISH TWIN COHORT (FTC) 
A sample set of 1492 individuals was ascertained from the study participants of the 
Finnish Twin Cohort (FTC) (one individual per pair) (Kaprio et al. 2002, Kaprio et 
al. 2002). The FTC includes both monozygotic and dizygotic twins, collected in 
several separate phases. The older cohort was initiated in 1975 and included13888 
same-sex pairs with known zygosity. The cohort was followed up in 1996 with a 
collection of an additional 8000 pairs with opposite sex born between 1938-1957 
(Kaprio et al. 2002). The younger Finnish twin cohorts, referred to as FinnTwin12 
and FinnTwin16, are longitudinal studies of behavioral development and health 
habits of Finnish twins enrolled at ages 11-12 and 16, respectively. The FinnTwin12 
cohort included five consecutive birth cohorts of Finnish twins born in the 1983-
1987 period and included 2295 complete pairs of monozygotic and dizygotic twins. 
In the FinnTwin16 cohort twin pairs born between 1975 and 1979 were identified 
and the cohort included 2618 complete pairs of monozygotic and dizygotic twins 
(Kaprio et al. 2002, Jelenkovic et al. 2011). 
 
4.1.2 International schizophrenia cohorts  
SGENE 
The phase I sample set of the SGENE consortium (study I) included 1433 cases 
diagnosed with schizophrenia spectrum psychosis and 33,250 controls from six 
countries: Iceland (N=646 cases, 32442 controls), Scotland (N=211 cases, 229 
controls), Germany (N=195 cases, 192 controls), England (N=105cases, 96 
controls), Italy (N=85 cases, 91 controls), and Finland (N=191 cases from the 
schizophrenia family sample and 200 controls, from the H2000 cohort). The phase II 
sample used for replication attempt of the preliminary findings included 3285 cases 
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and 7,951 controls from Scotland (N=451 cases, 441 controls) Germany (Munich, 
N=420 cases, 422 controls), Germany (Bonn, N=491 cases, 875 controls), The 
Netherlands (N=806 cases, 4,039 controls), Denmark (N=442 cases and 1,439 
controls), Norway (N=237 cases, 272 controls), and China (N=438 cases, 463 
controls)  
 
THE INTERNATIONAL SCHIZOPHRENIA CONSORTIUM (ISC) 
The ISC consisted of 3391 schizophrenia patients diagnosed with DSM-IV or ICD 
10 and 3181controls of European origin and was utilized as a replication sample in 
study III. The CNV calls for the cohort were obtained from the intensity data of the 
genotype probes on the Affymetrix 5.0 and 6.0 genotyping arrays by using Birdseye 
(Korn et al. 2008). A detailed description of the data set together with the CNV calls 
has been previously published (Stone et al. 2008).  
 
THE SWEDISH SCHIZOPHRENIA COHORT (SSC) 
A total of 5785 schizophrenia patients and 6348 controls were selected from the 
Swedish Schizophrenia cohort. The study subjects were identified from among all 
individuals hospitalized at least twice for schizophrenia since 1973 in Sweden. The 
controls had no hospitalization due to psychiatric disorders and were matched with 
the cases for age, sex, and county of residence (Bergen et al. 2012). All subjects 
were over 18 years old and gave their written informed consent to participate in the 
study.  
 
4.2 Methods 
4.2.1 Genome wide SNP arrays 
Data obtained from the genome-wide SNP genotyping chip arrays were used to 
identify copy number variants in all studies. In addition, the allelic information from 
the Genome-wide arrays was used to construct common SNP haplotypes in studies 
II and III. The GWAS data were generated at several time points for the study 
samples as a part of multiple research projects in different institutes using SNP 
arrays that were available at each time point (Table 4). 
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Table 4. Genome-wide genotyping arrays used for each sample set 
Study sample 
No. of 
Individuals GWAS array genotyping center 
Study 
number 
SGENE 
Phase I 
33683 Illumina HumanHap300 
deCode genetics, 
Iceland 
I 
SGENE 
Phase II  
11234 
Illumina HumanHap300, 
HumanHap550,  
HumanCNV370, 
Affymetrix GeneChip® 
GenomeWide  6.0 SNP 
Array, TaqMan 
Duke University, 
Bonn University, 
 deCode Genetics 
I 
NFBC 1966 4932 
Illumina Infinium 
370cnvDuo 
The Broad Institute, 
USA 
II, III 
HBCS 1586 
Human670K 
customBeadChip 
WTSI III 
Finrisk 173 
Human670K 
customBeadChip 
WTSI III 
H2000  2402 
Human610-Quad 
BeadChip, 
HumanHap 300 
WTSI III 
NFBC 1986 212 
Human670K 
customBeadChip 
WTSI III 
YFS 2308 
Human670K 
customBeadChip 
WTSI III 
FSFS  566 
Human670K 
customBeadChip, 
Illumina HumanHap300 
WTSI, DeCode 
Genetics 
III 
SSC 12133 
Affymetrix 5.0 SNP 
array 
The Broad Institute, 
USA 
III 
ISC 6572 
Affymetrix 5.0 SNP 
array 
The Broad Institute, 
USA 
III 
FTC 1492 
Human670K 
customBeadChip 
WTSI III 
 
4.2.2 Genotyping CNVs with Sequenom MassARRAY and Real-time 
quantitative PCR  
Verification of accurate CNV calling was conducted in a subset of 258 individuals 
(19 carrying a 22q11.22 deletion) who were genotyped using 31 SNPs selected from 
the GWAS arrays (Study III). Of the 31 SNPs, 26 overlapped the 22q11.22 deletion 
and the remaining five flanked it on both sides. The genotyping was performed 
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using Sequenom MassARRAY platform in 384-well plates with one iPLEX reaction 
using standard protocols specified by the manufacturer (Sequenom Inc., San Diego, 
CA, USA). Automated allele calling was manually verified using the MassARRAY 
Typer 4 software. The 384-well plate included eight water controls and eight inter-
plate duplicate samples for quality control. 
 
Individuals that had a homozygous stretch that corresponded to the deletion were 
further genotyped with Quantitative Real-time Polymerase Chain Reaction 
(QRTPCR). For this two probes were designed to both ends of the deletion area. The 
gene encoding for B-globin was used as a reference. The reactions were done in 
single plexes using SYBR
®
 GREEN PCR Master Mix on the ABI Prism® 7900 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The 
reactions for each probe were carried out in three repeats to control for sporadic 
variation. Each 384-well plate included six water controls for quality control. In 
addition eight individuals with known 22q11.22 deletion status were used to validate 
the measurements. 
 
4.2.3 Gene Expression measurement 
Genome-wide expression data were generated for 65 individuals of 18 families 
belonging to the Finnish schizophrenia family sample using Illumina HT-12 v4 
Expression BeadChip. Among these 65 individuals 12 were heterozygous carriers of 
the 22q11.22 deletion, 2 had a homozygous deletion and 51 were non-carriers. 
 
4.2.4 Detection of CNVs 
The CNVs were genotyped using normalized total intensity Log R ratio (LRR) and 
allelic intensity ratios, termed B-allele frequency (BAF) obtained from the probes on 
the Illumina genotyping arrays using PennCNV and QuantiSNP (Colella et al. 2007, 
Wang et al. 2007). Both software utilize a hidden Markov model for predicting the 
likelihood for a CNV. The model assumes that the observed intensities from an 
assumed Gaussian emission distribution are related to an unobserved copy number 
state at each locus. In addition, the neighboring loci are assumed to have similar 
copy number states and the probability of transition in copy number state is 
dependent on the distance between two markers (Wang et al. 2007, Wang et al. 
2008). The CNV calling was done independently for each cohort and the quality 
control (QC) was carried out by graphical clustering of LRR or BAF standard 
deviations and removing outlier samples from each cohort. In all cohorts, 
individuals were excluded if their LRR or BAF standard deviations were over 0.35 
and 0.07, respectively; the waviness factor was outside the range -0.04 -0.04; and 
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BAF drift exceeded 0.002, according to the software recommendations. Only those 
that exceeded the likelihood estimate of log Bayes factor > 10 in the CNV calls from 
QuantiSNP were included in the analysis. To control for false positive calls, each 
CNV was required to be detected with at least 10 probes. In each study the predicted 
CNV genotypes were confirmed by visual inspection of the LRR and BAF plots in 
Illumina Genome Studio or in R (Figure 12). 
 
 
Figure 12. Example of LogR Ratio and B-allele Frequency distribution for deletion 
and duplication. Each dot in the plot represents one marker on the GWAS array. 
Markers within the CNV are in red. For deletion the LogR Ratio reduces to -0.5 and 
no heterozygous genotypes (B allele frequency ~0.5) are observed. For duplication 
the Log R Ratio increases to 0.5 and the heterozygous genotype band is devided 
according to allele distribution to AAB (BAF~0.3) and ABB (BAF ~0.6) genotypes. 
4.2.5 Statistical testing and haplotype construction 
The statistical testing for association included Cochran-Mantel-Haenszel test, Fisher 
exact test, χ
2
-test, and t-test, analyses were conducted using PLINK software and R 
software (version 2.0.2) (Purcell et al. 2007). A statistical correction for multiple 
comparisons was included in all studies. In studies I and II a conservative 
Bonferroni correction (αB) was applied that divides the test-wise significance (α) 
level by the number of tests (m) (Equation 1).  
𝛼𝐵 =
𝛼
𝑚
  (1) 
 
The statistical significance in study III was achieved through 10 000 permutations. 
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The gene expression analyses were conducted using R (MA-ANOVA software 
package). The ancestral haplotypes were constructed from common SNPs by 
phasing with Beagle software (v3.1) (Browning et al. 2007). The SNP QC was 
performed according to standard procedures and included by-marker and by-sample 
success rates of >95%, and tests for the correct sex. Deviation from Hardy-Weinberg 
equilibrium (HWE) can be indicative of problems in genotyping. Each marker was 
tested for HWE using the exact test implemented in PLINK (Wigginton et al. 2005). 
Markers deviating from Hardy-Weinberg equilibrium with p<1×10
-6
 were removed. 
Kinship among study participants was calculated from genome-wide SNP data by 
estimating genome-wide sharing by identity by descent (IBD) likewise implemented 
in PLINK (Milligan 2003). Stretches of extended homozygosity were searched with 
PLINK to identify individuals that potentially carry deletions at a given site. For a 
stretch to be considered homozygous maximum two heterozygous genotypes were 
allowed per region. The pathway analysis for genes showing nominal statistical 
differences of mRNA levels (p < 0.05) between deletion carriers and non-carriers 
was conducted with DAVID bioinformatics resources 6.7 (Huang da et al. 2009). 
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5 Results and Discussion 
The role of large genomic CNVs in schizophrenia and neurodevelopmental 
phenotypes was studied in this thesis. The combined association findings obtained 
from studies I, II and III are presented in table 5. Specifically three deletions at 
genomic regions prone for recurrent CNV events were associated with schizophrenia 
(Study I). Carriers of large (>500kb) deletions were additionally found to have more 
often phenotypes related to abnormal neuronal development, including intellectual 
impairment (IQ<85) and repeated grades in school, as well as impaired hearing 
compared to non-carriers (Study II). Utilizing the unique genealogy of Finns, a 
deletion on chromosome 22q11.22 presenting as a founder mutation, was identified 
to associate with schizophrenia. Moreover, the non-schizophrenic carriers of the 
22q11.22 deletion had intellectual deficit and repeated grades in school (Study III) 
more often than non-carriers. The results combined in this thesis reveal a role for 
large genomic deletions in the pathogenesis of schizophrenia and intellectual 
abilities. The results further provide genetic evidence that schizophrenia is indeed a 
neurodevelopmental disorder and some part of the genetic predisposition at least in a 
subset of patients is non-specific to schizophrenia but is shared with other 
psychiatric disorders. 
Table 5. Deletions associated with schizophrenia and phenotypes of neuronal 
development combined from studies I, II, and III. 
CNV-locus phenotype N cases 
N 
CTRLs 
p-value OR Study 
1q21.2 SZ 4,718 41,199 2.9×10-5 14.83; 3.55-60.40 I 
15q12.1 SZ 4,718 41,199 6.0×10-4 2.73; 1.50-4.89 I 
15q13.3 SZ 4,718 41,199 5.3×10-4 11.54; 2.53-49.58 I 
> 500 kb 
deletions 
IQ<85 68 4,473 0.002 3.79; 1.54-8.14 II 
> 500 kb 
deletions 
Repeated 
grades 
189 5,352 0.0009 2.7; 1.47-4.67 II 
> 500 kb 
deletions 
Impaired 
hearing 
151 4,390 0.002 2.72; 1.38-4.95 II 
22q11.22 
(TOP3β) 
SZ 9,828 21,400 0.007 2.17 ; 1.18-2.87 III 
22q11.22 
(TOP3β) 
Repeated 
grades 
197 4,675 0.0034 3.99; 1.78-8-94 III 
22q11.22 
(TOP3β) 
IQ<85 69 4,781 0.033 4.60; 1.41-14.96 III 
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5.1 Recurrent microdeletions increase risk for schizophrenia 
(Study I) 
 
To identify genomic regions susceptible for recurrent CNV events, 9878 parent-
offspring transmission were scrutinized for de novo CNVs in an Icelandic discovery 
sample of 2160 trios (mother, father, and child) and 5558 parent-offspring pairs. The 
sample was ascertained from the general population but did not include any 
schizophrenia patients. The hypothesis was that if the identified de novo CNVs 
occur at a low frequency in a population despite a relatively high mutation rate 
(~1/10000 meiosis) they are likely to be under negative selection pressure. Thus, 
they could also have a role in severe mental disorders. The transmission analysis 
yielded 66 plausible de novo CNVs (15 duplications and 51 deletions in 62 non-
overlapping genomic regions) that were present in the offspring but not in the 
parents. Of the de novo CNVs, 32 were flanked by LCRs at least on one side (23 
from both sides). Of the 23 CNVs, flanked by LCRs on both sides, 18 (78%) were 
observed in more than one individual. The remaining 34 CNVs were not flanked by 
LCRs and 27 (79%) of these were identified only in a single discovery trio.  
 
The 66 plausible recurrent CNV sites that were identified to harbor de novo CNVs in 
the discovery population were further tested for association to schizophrenia in a 
multicenter sample of 1433 patients and 33 250 controls (SGENE phase I sample). 
Large deletions in three regions, 1q21.1 (OR=8.68; 95%-CI: 1.02-49.76), 15q11.2 
(OR=3.90; 95%-CI: 1.42-9.37) and 15q13.3 (OR=8.94; 95%-CI: 0.79-58.15) 
showed a nominal association for schizophrenia (p<0.05). From the Finnish sample 
set, only one control individual carried the deletion on chromosome 15q11.2. In the 
second phase the preliminary association for all three loci was replicated in a 
multicenter sample of 3285 cases and 7951 controls (SGENE Phase II sample) 
(p<0.05). In a combined analysis of phase I and phase II sample sets of all three 
deletions provided significant associations to schizophrenia (p<0.001) with large 
ORs (1q21.1: OR=14.83; 95%-CI: 3.55-60.40; 15q11.2: OR=2.73, 95%-CI: 1.50-
4.89; 15q13.3: OR=11.54, 95%-CI: 2.53-49.58). 
 
The 15q11.2 and 15q13.3 deletions that were associated with schizophrenia flanked 
the PWS region on 15q11-q13. The 15q11.2 deletion is included in the PWS type 2 
deletions (Figure 13) (Cassidy et al. 2012). PWS results typically from a 4-5Mb 
paternal deletion spanning 15q11.2-q13 or maternal uniparental disomy. The region 
contains imprinted uniparentally expressed genes that contribute to the phenotype. A 
maternally inherited deletion results in Angelman syndrome (AS). PWS is a 
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multisystem disorder with symptoms that include intellectual disability, behavioral 
phenotypes, obesity and characteristic dysmorphic features. Some of the PWS 
behavioral characteristics are similar to autism. In addition, psychosis is present in 
10-20% of PWS patients (Cassidy et al. 2012). Symptoms of AS typically include 
developmental delay, characteristic behavioral phenotype, dysmorphic features, and 
speech impairment (Williams et al. 2010). Reciprocal duplications of the PWS/AS 
region are phenotypically distinct from either PWS or AS. The duplication carriers 
lack the facial dimorphisms, but have varying learning deficits and autistic features 
(Boyar et al. 2001). 
 
 
 
Figure 13. Prader-Willi syndrome (PWS) showing the region on 15q11.1-q13.3. The 
horizontal bold red lines show the deleted regions that are associated with 
psychiatric disorders in the region. The type 1 and type 2 deletions indicate deletions 
that underlie PWS. The low-copy repeats in the regions are shown as bold grey lines 
and the common break points (BP1-BP5) that are associated with the deletions is 
also shown. Three regions are zoomed in: BP1-BP2, BP2-BP3, and BP3-BP4. 
Genes that underlie these regions are presented as bold blue lines (non-imprinted), 
bold green lines (paternally expressed), bold orange lines (maternally expressed, 
related to Angelman Syndrome). Note that these regions can contain additional 
transcripts that are not presented in the figure and that the figure is not fully in scale. 
The figure is adapted from (Cassidy et al. 2012). 
The most palusbile candidate gene in the 15q11.2 region is the cytoplasmic FMR1 
interacting protein 1 (CYFIP1). In addition to interacting with FMRP (Schenck et al. 
2001), CYFIP1 interacts with Rho GTPase Rac1. Rac1 is important for regulating 
axonal and dendritic outgrowth through actin reorganization and is necessary for the 
development and maintenance of neuronal structures (Luo 2000). In addition to 
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FMR1, other X-linked mental retardation genes have been implicated in the Rho/Rac 
pathway (Chelly et al. 2001).  
 
The 15q13.3 deletion disrupts a gene that encodes for CHRNA7. It is an α7 nicotinic 
acetylcholine receptor subunit, which is part of a ligand-gated ion channel that 
mediates fast signal transmissions at the synapses. It is expressed mostly 
presynaptically in the brain and has a role in modulating glutamate release at the 
synapses. Nicotine acetylcholine receptors had earlier been suggested to play a role 
in different diseases of the central nervous system, including Alzheimer’s disease, 
Parkinson’s disease, Tourette’s syndrome, ADHD, autism and schizophrenia (Gotti 
et al. 2004, Gotti et al. 2006). Evidence from GWAS also support a role for 
common genetic variants of cholinergic receptor genes in schizophrenia 
(Schizophrenia Working Group of the Psychiatric Genomics 2014). The 15q13.3 
deletion, identified in the present study has specifically been implicated in an 
increased risk for autism, intellectual disability, and epilepsy (Sharp et al. 2008, 
Ben-Shachar et al. 2009).  
 
Deletion of the corresponding α nicotinic acetylcholine receptor in mice causes 
impaired memory and learning (Fernandes et al. 2006, Hellier et al. 2012). These 
defects are suggested to originate from impaired cortical development of 
parvalbumin containing GABAergic interneurons (Lin et al. 2014). Deficits in 
parvalbumin-containing GABAergic interneurons have also been suggested to play 
role in cognitive deficits that present in schizophrenia (Lewis et al. 2012). 
Furthermore, nicotinic acetylcholine receptors, including the α7-receptor, have 
emerged as potential therapeutic targets for treating neurocognitive impairment in 
schizophrenia (Freedman 2014).  
 
The 1q21.1 deletion that was associated with schizophrenia overlaps several genes 
including two gap junction protein coding genes GJA5 and GJA8 that respectively 
encode for connexin 40 and connexin 50. Gap junction proteins enable direct 
metabolic and electrical communication between cells in the brain and other tissues 
(Sohl et al. 2005). Mutations in GJA5 and GJA8 have been associated with cardiac 
and eye phenotypes, respectively (Jiang 2010, Delmar et al. 2012). The GJA8 gene 
has earlier been associated with schizophrenia (Ni et al. 2007). The 1.4Mb 1q21.1 
deletion is also referred to as 1q21.1 deletion syndrome (OMIM#612474). The 
1q21.1 deletion syndrome is associated with high level of phenotypic variation, 
including a variable degree of intellectual disability, behavioral abnormalities, 
dysmorphic features, cardiac abnormalities, and cataracts. The deletion is reported to 
be de novo and also being inherited from unaffected or mildly affected parent. 
Duplications in the region are also associated with intellectual disability and autistic 
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features (Brunetti-Pierri et al. 2008, Mefford et al. 2008). In the present study, one 
Icelandic schizophrenia patients and 13 controls (12 from Iceland and one from 
Finland) had the corresponding duplication of 1q21.1. The 1q21.1 deletion has been 
associated repeatedly with schizophrenia and autism (Autism Genome Project et al. 
2007, International Schizophrenia Consortium 2008, Walsh et al. 2008, Sahoo et al. 
2011).  
 
5.2 Large deletions associate with impaired cognitive 
functioning (Study II) 
 
To study the impact of large over 500 kb deletions on neuronal development, a 
method termed phenotype mining that involves search of rich phenotype databases 
for measures correlated with genetic variation was used. A subset of seven pre-
selected phenotypes postulated to relate to abnormal neuronal development were 
studied in an unselected population sample of 4932 individuals ascertained from the 
NFBC 1966. These seven phenotypes included cognitive defect (IQ<85), a 
standardized measure of poor school performance, psychosis, epilepsy, neonatal 
seizures, cerebral palsy/perinatal brain damage, and impaired hearing (Table 3). A 
genome-wide scan for CNVs over 500 kb in the NFBC 1966 resulted in 634 CNVs 
in 529 individuals. A majority of the carriers (83%) had only a single CNV. The 
CNVs had a mean size of 991 kb and they spanned 165 non-overlapping CNV-
regions (CNVRs). A majority (65%) of the identified CNVRs included only a single 
CNV. Deletions were significantly underrepresented compared to duplications 
(p=8.6×10
-28
). Also no homozygous deletions were observed. Five individuals with 
trisomy 21 and three with trisomy X were identified and removed from subsequent 
analysis with the phenotypes.  
 
Individuals with large deletions (N=160) had higher frequency of intellectual defect, 
which is defined as IQ<85 (OR=3.79, 95%-CI: 1.54-8.14), and learning difficulties 
indicated as repeated grades in school (OR=2.7, 95%-CI: 1.47-4.67) compared to 
individuals with no CNVs (N=4381). All individuals with intellectual defect had 
also repeated grades. However, even after excluding these individuals, learning 
difficulties were twice as common among deletion carriers compared to non-carriers 
(OR=2.02, 95%-CI: 0.84-4.24). In addition, impaired hearing was more frequent 
among carriers of large deletions compared to individuals with no CNVs (OR=2.72, 
95%-CI 1.38-4.95). However, the frequency of psychosis did not differ significantly 
between the deletion carriers and non-carriers (OR=1.25, 95%-CI 0.33-3.38). 
Further, none of the phenotype categories were significantly overrepresented 
collectively among individuals with duplications (p<0.05).  
Results and Discussion 
 
 76  
 
 
A marked co-occurrence of the three overrepresented phenotype categories of 
IQ<85, repeated grades, and impaired hearing was observed among the carriers of 
large deletions. Of the 160 deletion carries, 24 had at least one of the phenotypes, 10 
at least two phenotypes, and three individuals had all three phenotypes. The 
overrepresentation of the three phenotypes with deletion carriers was accounted for 
by 18 distinct deletions. The deletion carriers of 11 of the 18 deletions had at least 
two of the phenotypes (Table 6). 
 
In additional analysis, we investigated also whether the age of achieving early 
developmental milestones would differ between carriers of large deletions and non-
carriers. The deletion carriers were less likely to know their own name at the age of 
3 (p=0.03, OR = 0.33; 95%-CI: 0.09-0.93) and more likely to have had abnormal 
hearing at age of four (p=0.0012, OR3.54; 95%-CI:2.58-7.24). However none of 
these differences remained significant after Bonferroni correction for 44 tests. The 
nominal association with impaired hearing at the age of four was not overlapping 
with the association detected for impaired hearing measured at 14 years old.  
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Table 6. The 18 deletions that underlie the associations with IQ<85, repeated 
grades, and impaired hearing in the NFBC 1966. 
Chr Start End Tot obs. 
IQ < 
85 
Repeated 
grades 
Impaired hearing 
2p16.3 50.0 51.6 1 ID25 ID25 – 
4q24–q25 104.5 109.4 1 – – ID26 
4q35.2 188.4 189.5 1 – ID27 ID27 
4q35.2 189.5 190.7 3 ID28 ID28 – 
6p22.3 22.2 22.8 1 – – ID30 
6q16.1 94.4 95.0 4 ID31 ID31 – 
7p12.1 53.1 53.8 13 – ID34, ID35 ID32, ID33 
7q11.21 64.2 64.8 1 – ID36 – 
8p23.1 7.2 7.8 17 – – ID37 
10q11.22 46.2 46.8 25 ID16 ID16 
ID14, ID15, 
ID16 
10q26.2–q26.3 128.3 132.7 1 – – ID18 
11p14.3 21.7 22.3 1 ID19 ID19 – 
15q11.2 21.9 22.7 13 – ID8, ID12 – 
15q13.1–q13.2 28.7 30.3 1 ID20 ID20 ID20 
16p11.2 29.5 30.1 3 ID21 ID21 – 
17q21.31–
q21.32 
41.5 42.0 1 – ID22 ID22 
22q11.21 17.2 19.8 1 ID23 ID23 ID23 
22q11.22–
22q11.23 
21.3 22.0 3 – ID24 – 
 
The associations between large deletions and intellectual phenotypes were 
accounted for by deletions in 14 genomic regions (16 individuals), from which eight 
were associated only with intellectual disability. These include the 15q13.3 deletion 
found earlier to be associated with schizophrenia (study I). The 14 regions included 
two other schizophrenia associated deletions at 2p16.3 and 22q11.2 (International 
Schizophrenia Consortium 2008, Stefansson et al. 2008, Kirov et al. 2009). All of 
the carriers of these deletions had IQ<85 and also had repeated grades in school, but 
did not have diagnosis for psychosis in the birth cohort. One individual likewise 
with IQ<85 and repeated grades in school had a 16p11.21 deletion. Reciprocal 
duplications in this region are associated with schizophrenia and autism (Weiss et al. 
2008, McCarthy et al. 2009).  
 
The enrichment of large deletions among individuals that have repeated grades in 
school suggests that large deletions affect cognitive skills on a general level in 
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population. It has been obligatory since 1921 that children aged seven attend a 
public elementary school in Finland. A postponement or exemption can be granted if 
the child has intellectual disability or delayed development. The compulsory public 
elementary education enables the systematic assessment of a child’s school 
performance. Compulsory schooling is generally nine years and lasts until age of 16. 
Among all children born in 1966 in Northern Finland, 2.2% did not attend regular 
school and 3.8% were at a lower grade than expected for that at the age of 14. 
Among those children in lower grade 44% of cases had an IQ that was below 85 
(Rantakallio et al. 1986). Individuals who have repeated grades in school have been 
reported to have an increased risk for psychiatric disorders including schizophrenia 
(Isohanni et al. 1998). 
 
The results suggest that large deletions have a stronger cumulative impact on traits 
related to early onset of intellectual disabilities, including milder subclinical 
features, than they do for either psychosis or schizophrenia. This observation is in 
line with findings from other studies that demonstrate that those CNVs that underlie 
schizophrenia are associated with a broad range of clinical variability. Even though 
conferring a marked risk for schizophrenia they are still associated with incomplete 
penetrance of generally less than 10% for schizophrenia (Vassos et al. 2010). 
Control individuals that carry CNVs associated with neuropsychiatric disorders 
perform in measures of cognitive ability intermediate to schizophrenia patients that 
carry the CNVs and non-carrier controls (Stefansson et al. 2014). Moreover, the risk 
conferred by the CNVs tends to increase towards earlier onset disorders including 
intellectual disability, congenital malformations, and autism spectrum disorders 
(Cooper et al. 2011, Malhotra et al. 2012, Kirov et al. 2014). Consistently, the 
burden of pathogenic CNVs is even higher among patients of childhood onset of 
schizophrenia compared to adult onset schizophrenia (Ahn et al. 2014).  
 
5.3 Rare deletions in young isolate population represent 
founder mutations (Study II) 
The enrichment of neurodevelopmental phenotypes among carriers of large 
deletions in the NFBC 1966 could be attributed to 18 distinct deletions (Table 6). Of 
these 18 deletions, eight were observed in more than one individual. Motivated by 
the Finnish population history, the possibility that some of these deletions would be 
founder mutations of a singular ancestral was investigated. Allelic haplotypes were 
constructed from the common SNPs included in the SNP array. Seven of the eight 
deletions that had multiple carriers were nested in a single ancestral haplotype. In 
addition, the parental birthplaces of the carriers of each deletion demonstrated 
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regional clustering further supporting common ancestry for the carriers and that the 
deletions were shared IBD between the carriers.  
 
Genetic variants with strong adverse effects are likely to be infrequent in the 
population. An extreme example of such a variant are the disruptive recurrent de 
novo deletions associated with schizophrenia in study I. However, even these 
deletions are occasionally inherited. The rarity of these variants and the high level of 
baseline variation make it difficult to accrue statistical evidence that any particular 
variant is associated with a given trait. In recently expanded population isolates, 
however, the high levels of genetic drift that occur could potentially generate 
relatively high frequencies for high impact variants, and thereby create an 
opportunity to identify associations of particular phenotypes for single variants 
(Peltonen et al. 2000). The prevalence of certain complex neurodevelopmental 
phenotypes, including schizophrenia and intellectual disability in Finland shows a 
marked gradient from the Southwest to Northeast of Finland (Figure 14) 
(Rantakallio et al. 1986, Hovatta et al. 1997, Heikura et al. 2003, Arajarvi et al. 
2005, Perala et al. 2008). This prompted us to pose the following question in study 
III: Could the increased prevalence of common disorders in particular Finnish 
regions be at least partially due to a similar local enrichment of rare risk variants? 
(Varilo et al. 2004)? 
 
 
Figure 14. Regional variation seen A) in the relative risk for schizophrenia and B) 
the frequency of intellectual disability as measured by the rate of issuing disability 
pensions. The pattern follows also the internal migration movement that occurred in 
Finland starting in the 16th century. The early and late settlements are separated by 
the grey border. 
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5.4 Utilizing population isolates in identifying rare variants 
underlying complex traits (study III) 
To identify deletions that because of recent bottlenecks would have become 
enriched to regions with high relative risk for schizophrenia in Finland, a genome-
wide scan for rare (frequency <5%) genomic deletions of over 20 kb was performed 
in two geographically based Finnish population samples. The two samples were 
assembled from the capital region which represents the mean relative risk of 
schizophrenia (N=1586, HBCS) and from the North-East Isolate with a high relative 
risk of schizophrenia (N=173, Finrisk). The scan resulted in 5313 putative rare 
deletions with a mean size of 89.4 kb and which comprised 1041 non-overlapping 
genomic loci. 
 
Initial statistical comparisons between the sub-isolate population sample and the 
“whole Finland population sample” (from the capital region) for all 1041 putative 
deletion loci were conducted. For statistical significance, it was required that the 
difference in frequency between the sub-isolate sample and the whole Finland 
sample would occur by chance less frequently than once in 1000 permutations, 
corresponding roughly to the number of loci tested. Of the 1041 putative deletion 
loci, three loci displayed a significantly higher frequency of deletions in the sub-
isolate population sample (empirical p-value <0.001 after 1000 permutations). To 
confirm the deletion loci for further analyses, a manual inspection of the deletion 
genotypes using intensity distribution plots in the three regions including testing for 
Hardy-Weinberg equilibrium was conducted. Finally, two deletion loci on 
chromosomes 4q12 and 22q11.22 passed the QC. These two deletions were found to 
be significantly more common in the general population originating from the “high 
risk” region compared to the capital area “low risk” population. The 4q12 deletion 
spanned 181.7 kb and was carried by six individuals from the isolate and none from 
the whole Finland sample (p=8.7×10
-7
). The 22q11.22 deletion spanned 243.9 kb 
and was carried by 18 individuals from the sub isolate sample and one from whole 
Finland sample (p=8.55×10
-18
). 
 
A single ancestral origin was evident for both deletions, as determined by shared 
SNP haplotypes observed in both the sub-isolate population sample and the whole 
Finland population sample (total N=1793). For the 4q12 deletion, carriers shared a 
single 2.25 Mb haplotype (248 kb proximal and 2.0 Mb distal to the deletion), while 
carriers of the 22q11.22 deletion shared a 289 kb haplotype (167 kb proximal and 
122 kb distal to the deletion). Both deletions must have arisen relatively recently. 
We deduced this possibility as both the 4q and 22q haplotypes were present in non-
carriers of the deletions, with population frequencies of 1.1% and 13.0%, 
respectively. In arriving at these values, we assumed full LD between their proximal 
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and distal portions. Based on the haplotype sizes and frequencies, the 4q12 deletion 
probably arose more recently than the 22q11.22 deletion.  
 
Next, the two deletions, enriched in the sub-isolate sample, were tested for 
association with schizophrenia in a sample of 185 patients and 747 controls, that 
originated from the isolate. Of the two deletions, the one on 22q11.22 showed 
significant association with schizophrenia within the isolate sample (OR=1.84, 95%-
CI: 1.05-3.23). The deletion on 4q12 showed no such difference (p=0.14) however. 
The initial association of the 22q11.22 deletion with schizophrenia was further 
followed up in the whole Finland and non-Finnish European schizophrenia case-
control samples of 467 and 9176 patients, and 11 124 and 9529 controls, 
respectively. The deletion showed nominal association in the whole Finland sample 
(OR=2.63 95%-CI: 1.28-5.59) but did not reach statistical significance in the non-
Finnish samples (OR=2.17, 95%-CI: 0.81-5.80). The combined estimate for 
association with schizophrenia was with OR 1.84 (95%-CI 1.18-2.87, p=0.007).  
 
The relationship between the 4q12 and 22q11.22 deletions and seven 
neurodevelopmental phenotypes utilized in Study II was analyzed in 4872 non-
schizophrenic individuals of the NFBC 1966. Carriers of the 22q11.22 deletion had 
significantly more intellectual disability compared to non-carriers (OR=4.6, 95%-CI: 
1.41-14.96, p=0.03), and an even greater overrepresentation of milder learning 
difficulties (OR= 5.9, 95%-CI: 1.78-8.94, p=0.003). However, although the deletion 
showed an increased risk for psychosis (excluding a diagnosis of schizophrenia), the 
test for association did not reach statistical significance (OR=4.1, 95%-CI: 0.55-
30.17, p=0.2). No phenotypes were significantly overrepresented among the 4q12 
deletion carriers.  
 
Cognitive functioning was also evaluated among 19 schizophrenia patients of 
Finnish schizophrenia families that carried the 22q11.22 deletion and 547 patients 
without the deletion. The carriers performed slightly worse in tests of CVLT 
assessing verbal memory after short delay (B=-1.5, p=0.03), and showed similar 
tendency in other measures including processing speed and executive functioning, 
attention and working memory, although not reaching statistical significance. Four 
individuals were found to be homozygous for the 22q11.22 deletion. All four 
individuals displayed cognitive impairment that ranged from poor performance on 
tests of executive function and information processing to moderate intellectual 
disability. Two of them also had a diagnosis of schizophrenia.  
 
The 22q11.2 region has not been implicated with schizophrenia in previous linkage 
studies conducted in the isolate or other Finnish schizophrenia families (Hovatta et 
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al. 1998, Hovatta et al. 1999, Ekelund et al. 2000, Paunio et al. 2001). The 
identified deletion spanned 240 kb and was ~500 kb distal to the most commonly 
deleted region in VCFS, overlapping the distal 22q11.2 deletion syndrome region 
(Figure 15) (Tan et al. 2011). The deletion flanked two genes, from which the other 
one was an immunoglobulin variant and the other one was a gene encoding for 
topoisomerase 3 β (TOP3β). The phenotypic impact of the deletion reported here 
likely derives from its effect on TOP3β. The deletion directly disrupts this gene, 
down regulates its mRNA levels, and does not alter transcript levels of other genes 
in the deletion region. Recent surveys of de novo mutations have yielded both direct 
and indirect (through biological networks) suggestive genetic evidence connecting 
TOP3β with neurodevelopmental phenotypes (O'Roak et al. 2012, Xu et al. 2012). A 
recent report described a single individual, of unspecified ethnic origin, who had a 
240 kb deletion that appears to be identical to the one presented here, which 
demonstrated speech delay and minor physical abnormalities (Tan et al. 2011). 
More suggestively, Xu et al. recently reported a 22q11.22 deletion covering the 
same region, as well as a de novo TOP3β missense mutation in Afrikaner 
schizophrenia patients (Xu et al. 2012). Finally, an autistic patient with 
macrocephaly, cognitive impairment, and defective social behavior and language 
development carried truncating mutations in three genes (RCAN1, CHD8 and 
CUBN) that are members of a β-catenin-linked pathway that also includes TOP3β 
(O'Roak et al. 2012). 
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Figure 15. Schematic presentation of the 22q11.22 deletion region. Deletions that 
are associated with VCFS and distal 22q11.2 deletion syndrome are shown in bold 
blue lines and the LCRs facilitating these mutation events are presented in grey. 
Known disease related OMIM genes are shown in bold orange lines. The break point 
associated SNPs are marked above the 240 kb deletion. The genes overlapped by 
the 240 kb 22q11.22 deletion are presented below the deletion, with exons 
presented as bold orange lines. 
The deletion had a single dosage dependent association with the TOP3β expression 
in lymphoblastoid cell lines of 65 individuals (51 non-carriers, 12 heterozygous 
carriers, and 2 homozygous carriers) of 18 families ascertained from the Finnish 
schizophrenia family study. The expression level of TOP3β in non-carriers (269.99, 
95%-CI=249.18-290.79) was twice that of heterozygotes (127.61, 95%-CI=103.92-
151.30), while homozygous deletion carriers had no detectable transcript. The 
deletion had no genome-wide significant effect on mRNA levels of any other gene. 
However, 813 genes (858 of 9872 probes) showed nominal differences (p<0.05) in 
their respective mRNA levels between deletion carriers and non-carriers. From this 
set of 813 genes, we evaluated whether any functional gene category, plausibly 
affected by the down-regulation of TOP3β would be enriched among deletion 
carriers compared to non-carriers. Genes involved in two related categories, 
translation and ribosomal complexes displayed a 3.1 and a 2.8-fold enrichment, 
respectively, (p=6.2×10
-8
 and 2.8×10
-10
), which could imply that the 22q11.22 
deletion exerts its phenotypic effect via disturbed translational regulation (Table 7) 
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Table 7. Functional annotation of genes that differ in mRNA levels between the 
22q11.22 deletion carriers and non-carriers. 
Term GO ID %-of genes 
Fold-
enrichment 
p-value 
Biological process 
    
Translation 0006412 4.8 3.1 0.00014 
Cellular component 
   
Ribonucleoprotein complex 0030529 7.0 2.8 1.10×10
-7
 
Cytosol 0005829 12.1 1.9 1.80×10
-5
 
Ribosome 0005840 3.1 3.1 0.0061 
Ribosomal subunit 0044391 2.2 3.6 0.024 
Molecular function 
   
mRNA binding 0003723 7.0 2 0.0037 
Structural constituent of 
ribosome 
0003735 2.7 3.4 0.013 
 
Biochemical investigations revealed functions for the TOP3β protein that could 
explain the phenotypic effect of its deletion. The TOP3β protein formed a protein 
complex with FMRP via Tudor domain–containing protein 3 (TDRD 3) through the 
immunoprecipitation from Human Embryonic Kidney 293 cells (HEK293). FMRP 
is a polyribosome associated RNA-binding protein that inhibits the translation of 
pre- and post-synaptic RNAs (Laggerbauer et al. 2001, Darnell et al. 2011). The 
dysregulation of translation resulting from the inactivation of FMRP causes fragile 
X syndrome (FRAX, OMIM #300624) (Bassell et al. 2008). FRAX is the second 
most common form of intellectual disability after Down Syndrome and results from 
(CGG)n repeat mutations at the 5´UTR of FMR1, which results in hyper methylation 
of the repeat and the following CpG island. The hypermethylation further results in 
transcriptional silencing of the FMR1 encoding for FMRP (Fu et al. 1991, Pieretti et 
al. 1991, Devys et al. 1993, Rousseau et al. 1995). 
 
TOP3β was found to bind mRNA, which suggests that it is a component of cytosolic 
messenger ribonucleoproteins (mRNPs). The protein complex was also present in 
the neuronal cells of mouse brain lysates and TOP3β had similar intracellular 
localization and trafficking as the nucleo-cytoplasmic shuttling proteins FMRP and 
TDRD3. TOP3β is a type IA topoisomerase that alters DNA topology (Viard et al. 
2007), However, it was found to be catalytically active also on RNA. Furthermore, 
the TOP3β-TDRD3-FMRP- complex was found to be a component of translating 
mRNPs, reported already earlier for FMRP (Siomi et al. 1996). 
 
TDRD is multidomain protein that binds to the exon junction complex (EJC), a set 
of proteins that are deposited as a consequence of splicing upstream of mRNA exon-
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exon junctions, and likely mediates the interaction between TOP3β and FMRP 
(Tange et al. 2004). The interaction of TDRD3 with EJC was not disrupted even 
though binding sites for FMRP or TOP3β were deleted, suggesting that it mediates 
the concomitant integration of TOP3β and FMRP into mRNPs. Furthermore, 
TDRD3 deficient cells also prevent TOP3β recruitment to polysomes, but had not 
effect on FMRP. Together these findings of topoisomerase activity on RNA 
substrates suggest that it is involved in the metabolism of FMRP-bound mRNAs.  
 
The relevance of TOP3β in neurodevelopmental disorders were further supported by 
an accompanying study that also concluded that TOP3β is an RNA topoisomerase 
that interacts with FMRP. A Missensense mutation in FMR1 identified in a patient 
with the FRAX phenotype also eliminates the TDRD3 mediated TOP3β interaction 
with FMRP: a finding that further supports the role of this complex in the 
pathogenesis of mental disorders. Moreover, TOP3β was found to bind to mRNAs 
of multiple neuronal genes, also linked with schizophrenia and autism. In addition, 
synapse formation is defective in Top3β mutant flies and mice, just as it is defective 
in FMRP mutant files and mice, suggesting that TOP3β acts in concert with FMRP 
and they both are important for normal neuronal development (Xu 2013). In 
conclusion, TOP3β is an RNA topoisomerase that seems important for 
neurodevelopment via systems that involve interaction with FMRP, translational 
regulation and possibly RNA topoisomerase activity.  
 
5.5 Limitations of the study 
The most significant limitations of the studies described in this thesis are the limited 
sample sizes for complex disease genetics, lack of replication in study (II) and the 
technical challenges related to reliably identifying and genotyping CNVs from SNP 
array data. 
 
5.5.1 Sample size and statistical power 
Statistical confidence for deducting association signals is proportional to the sample 
size, allele frequency, disease prevalence, and the risk associated with the variants 
studied (Psychiatric Gwas Consortium Coordinating Committee et al. 2009). Due to 
limited samples sizes, the studies combined in this thesis were limited to studying 
variants of large effects (OR>2). Genotypic relative risks associated to common 
variants (frequency >5%) in GWAS have been commonly found to be below 1.2 and 
thus those variants were beyond the statistical power of the studies included here. 
On the other hand the rarity of the high risk variants introduces a major caveat for 
the statistical power and the genome-wide significance level (P = 5×10
-8
), which 
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could not been reached in any of the studies in this thesis. This is despite that the 
risks associated with the variants were markedly larger than those generally 
expected for complex traits (OR up to 14). In order to limit the number of statistical 
comparisons and need for statistical correction the studies were limited to 
investigating a small proportion of the total variation at each time. In study I only de 
novo CNV sites were included which limited the number of comparisons to 66, 
corresponding to Bonferroni corrected p-value of 7.6×10
-4
. Similarly, the number of 
tests was controlled in studies II and III. In study II a global burden of only very 
large CNVs was estimated rather than studying individual variants. Study III was 
limited to rare relatively large CNVs that were more common in the isolate 
population.  
5.5.2 Replication 
Due to the stochastic correlations, findings should be replicated in additional sample 
sets to confirm the preliminary association result. In studies I and III replications for 
the preliminary findings are provided in larger sample sets. However, a lack of 
within-study replication is a shortage in study II. The results of study II, therefore 
must be considered within the context of the body of evidence emerging in the field. 
 
5.5.3 Technical limitations 
The quantitative measuring of DNA copy number is still challenging due to the high 
levels of stochastic variation in the marker intensities on a SNP array. The stochastic 
error can be reduced by requiring multiple probes (e.g. 10 or more) to assign each 
CNV and also by validating the CNV genotypes by using complimentary methods, 
such as quantitative real-time PCR (used in studies I and III), or FISH (used in study 
I). Nonetheless many of these complimentary methods are likewise unreliable and 
laborious to conduct. Moreover, requirement of multiple probes on a GWAS array to 
define a CNV will limit the detection of smaller CNVs. If an average SNP density in 
a GWAS array would be 1 SNP/kb, when requiring more than 10 probes to assign a 
valid CNV call this will already limit the detection of CNVs below 10-20 kb. Also 
genomic regions enriched with CNVs are prone to false positive calls due to 
repetitive sequences and are also less well covered in the genotyping arrays used. 
One way to control for false calls is by manually inspecting the intensity distribution 
plots.  
 
5.5.4 Phenotyping 
Genetic studies often start by defining a phenotype and then searching genotypes 
that account for some part of the variation observed for the defined phenotype. 
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However, when considering psychiatric traits, they are often imprecisely defined in 
a biologically meaningful way and difficult to assess objectively. This can restrict 
the accuracy by which they can be designated as being shared between individuals. 
Study II approached this question by using the genotype (carrier of large deletions) 
as a starting point in the analysis and then looking what phenotypic features the 
carriers share with each other. The idea being that in contrast to the phenotype, the 
genotype can be objectively and precisely measured. This “phenotype mining” 
method requires consideration of evaluating the significance of associations detected 
between traits and genotypes. While the genetic space is well defined, the total 
number of phenotypes cannot be generically described and nor can their degree of 
independence from each other be easily defined. For these reasons, the analysis in 
study II was limited to seven phenotype categories postulated to be relevant for 
neuronal development. 
 
5.5.5 Population stratification 
Population stratification is a major confounder of association analysis and affects 
analyses of both rare and common variants. Study I focused on de novo variants and 
although the study sample consisted of multiple populations, the mutation rates can 
be assumed to be similar across populations. In addition, variants associated with 
very large dominant effects, such as identified in the study I, are not likely to grow 
in frequency even in young founder populations, such as in the Finnish population. 
Study II was a geographically based population study, which does not involve 
stratification caused by sampling to cases and controls. Study III utilizes internal 
genetic structure to identify variants possibly contributing to schizophrenia. In this 
study the stratification was controlled by using parental birth places of the 
participants and using MHC statistics designed for stratified analysis. It is, however, 
still likely that the associations observed, particularly involving the whole Finland 
sample are also affected by population sub-structure. 
 
5.5.6 Clinical and biological interpretation of the findings 
The genetic findings of this study remain clinically unspecific. An OMIM ID has 
been granted for the deletions identified in study I and in some cases these may be of 
diagnostic importance. However, the clinical picture related to the carriers of these 
deletions varies substantially and they also include incomplete penetrance. For these 
reasons, clinical findings involving these deletions should still be interpreted with 
caution. In study III, a fully penetrant recessive effect of TOP3β deletion was 
observed. Yet, this finding was observed with four individuals and was associated to 
heterogenic phenotype, which is why clinical implications should also in this case be 
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interpreted cautiously. The exact biological mechanisms related to the genetic 
findings in this thesis likewise remain incompletely understood. In many cases the 
associated deletions overlap multiple genes and the causative gene or genes are not 
known. Study III provides most detailed investigation of the biological relevance of 
the finding. However, the direct mechanism related to the TOP3β deletion and the 
neurodevelopmental phenotypes also remains uncertain. 
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6 Conclusions 
We have identified large genomic deletions that predispose to a set of phenotypes, 
that are hypothesized to reflect abnormal neuronal development, including 
schizophrenia, intellectual disability, and milder learning difficulties. In addition to 
the global burden of large deletions in neuronal development, we specifically 
identified four genomic deletions at 1q21.1, 15q11.2, 15q13.3 and 22q11.22 
(TOP3β) that were associated with schizophrenia and impaired intellectual 
functioning. Of the deletions three (1q21.1, 15q12.1, 15q13.3) represent recurrent 
mutations, and even though they can also be inherited, as in the case of 1q21.1 
deletion (Mefford et al. 2008), they often occur de novo in patients. The fourth 
deletion, overlapping TOP3β is a founder mutation that because of recent population 
bottlenecks has become enriched in Finland. In contrast to the other three deletions, 
the TOP3β deletion was found to have a particularly strong recessive effect. 
Biologically, the genes overlapped by the four deletions suggest the involvement of 
synaptic genes with prominent roles in the development and maintenance of 
neuronal networks to be relevant in schizophrenia. Furthermore, the regulation of 
synaptic translation is suggested to be of relevance in the etiology of schizophrenia 
and this implication is especially supported by the deletion of TOP3β and its 
association with FMRP. The role of the FMRP pathway has been further supported 
by findings from other studies of CNVs, as well as rare and de novo sequence 
variants in schizophrenia (Kirov et al. 2012, Ripke et al. 2013, Fromer et al. 2014, 
Purcell et al. 2014). 
 
Three major themes emerge from the results of this study. First, a small portion of 
the genetic risk of schizophrenia is due to rare high risk variants, namely large 
chromosomal deletions. The second theme is the links between developmental 
phenotypes, namely cognitive functions and mental disorders. All of the deletions 
associated with schizophrenia described in this thesis have also been linked with 
intellectual functioning by the present study and also by studies conducted by other 
groups (Malhotra et al. 2012, Stefansson et al. 2014). Importantly, the results imply 
the role of large deletions, including those associated with schizophrenia, and also in 
milder intellectual deficits that can manifest as learning difficulties. These 
observations agree well with decreased cognitive performance reported in 
schizophrenia (Heinrichs et al. 1998, Mesholam-Gately et al. 2009, Fioravanti et al. 
2012). Third, the genetic studies are moving towards the systematic assessment of 
rare variants in complex traits, thus different study designs may be adopted. For 
example, in the present study we have demonstrated the potential usefulness of large 
population samples in studying the relationship of rare genetic variants across 
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different diagnostic entities – a method we have named phenotype mining. In 
addition, as demonstrated earlier for Mendelian disorders, our findings of the TOP3β 
deletion support that isolated founder populations can also assist studies of rare 
variants in complex traits, such as schizophrenia and intellectual disability.  
 
As a final comment, the synthesis from the wealth of genetic evidence from both 
common and rare variants accumulated during the last 10 years including the results 
presented in this thesis indisputably demonstrate that genetic susceptibility is shared 
across psychiatric diagnostic boundaries (Figure 16). The strongest correlations 
arises between schizophrenia, bipolar disorder, and major depressive disorder 
primarily accounted for by common variants (Cross-Disorder Group of the 
Psychiatric Genomics et al. 2013). The findings from rare variants support shared 
genetic factors particularly between schizophrenia, autism, and intellectual disability 
(Fromer et al. 2014, Kirov et al. 2014, Purcell et al. 2014). However, less evidence 
supports a major role for rare high risk CNVs in affective psychosis including 
bipolar disorder, and the impact of the CNVs studied in this thesis seems to be 
strongest in the early onset cases (Zhang et al. 2009, Grozeva et al. 2010, Malhotra 
et al. 2011, McQuillin et al. 2011, Malhotra et al. 2012, Priebe et al. 2012, Grozeva 
et al. 2013).  
 
 
Figure 16. Genetic sharing between psychiatric disorders. Evidence from GWAs 
studies, studies of rare and de novo CNV studies and sequencing studies. 
The question arises: Why do the same genetic variants lead to such variable 
phenotypic presentations and significantly variable age of onset? One obvious 
answer is that studies have mostly estimated the impact of gene variants to 
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psychiatric end-diagnosis, but not to those biological processes more directly 
affected by the gene variants. Moreover, individual gene variants do not act in a 
vacuum but in combination with other possibly modifying genetic factors and 
environment. A plethora of environmental factors including viral infections, birth 
complications, early life insults, famine, etc. have been associated with increased 
risk for schizophrenia (Sullivan 2005). It has been speculated that the genetic risk 
for schizophrenia could emerge from a cumulative risk of thousands of low risk 
variants on a pathway rather than from a single node on the pathway (Sullivan 
2012). This suggestion is consistent with the fact that no Mendelian form of 
schizophrenia has been identified – even in childhood onset forms of schizophrenia. 
Moreover, rare disruptive mutations in genes with common variants associating with 
schizophrenia such as NRXN1, CACNA1C, and TCF4, do not cause schizophrenia 
but rather they cause intellectual disability or autism (Sullivan 2012). 
 
Considering the genetic evidence to date for psychiatric disorders, the common 
variants seem to play a more prominent role in later (early adulthood) onset 
disorders, whereas rare high risk variants are identified more often in patients with 
early onset disorders. For example, the load of rare disruptive CNVs is even higher 
in childhood onset of schizophrenia compared to the general form of schizophrenia 
(Ahn et al. 2014). This seems to be evolutionarily consistent with the associated 
reduced fecundity with the most severe forms of mental disorders. Current genetic 
evidence suggest that the effect of one highly pathogenic variant, such as a high risk 
CNV, is not biologically equal to the cumulative sum of multiple less pathogenic 
variants, such as common SNPs with small effects. This is analogous to the situation 
whereby driving a car into a wall once at 100 km/h is not same as driving a car 10 
times into a wall at 10 km/h. The consequences are quite different. When translating 
this analogy and applying it to the genetic risk for neurodevelopmental disorders, it 
is tempting to speculate that if a variant exceeds a certain threshold of pathogenicity, 
it will exert its effect at an early stage of “crude” neurodevelopment resulting more 
often in early onset disorders. However, the cumulative sum of variants with low 
pathogenicity (polygenic score of common variants) will not exceed this threshold 
(at least not very often) and would thus express its effect during a later 
developmental “fine-tuning” stage, which will more often result in later onset 
disorders.  
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7 Concluding remarks and future 
prospects 
What have we learned from the genetic studies of schizophrenia? First of all, we 
now know that schizophrenia is a biological disorder to begin with. Schizophrenia is 
as biological as any somatic disorders that are generally perceived as being 
biological in nature. In fact schizophrenia and other severe mental disorders have 
generally the highest heritability estimates compared to other complex diseases and 
these have now started to be formulated into specific biological pathways. It should, 
however, be emphasized that this does not mean that schizophrenia is solely a 
genetic disorder; just as any other complex diseases are not solely genetic for that 
matter. In addition to the genetic predisposition for schizophrenia, a number of 
environmental factors, including pre and postnatal, social, childhood and later life 
events are associated with an increased risk for schizophrenia. The currently widely 
accepted model perceives schizophrenia to be a neurodevelopmental disorder where 
the risk formulates gradually in concert with genetic makeup together with social 
and environmental factors (Rapoport et al. 2012, Howes et al. 2014). The second 
lesson is that the genetic architecture of schizophrenia is very similar to other 
complex traits, including human height and many complex diseases that pile up 
mostly from a multitude of risk variants; each of which has a modest effect. Third, 
genetic associations enriched in genes expressed in the brain and neurons, 
demonstrated that schizophrenia can truly be considered as a neuronal disorder, not 
merely a disorder that affects the brain. With the discovery of neuroleptic drugs a 
view emerged of schizophrenia being a disorder of dopaminergic system, and then 
later on the glutaminergic dysfunction hypothesis emerged (Coyle 1996). Genetic 
evidence further supports that these pathways are of etiological relevance for the 
disease. Further, since these systems are known therapeutic targets, it highlights the 
possibility to extract also novel therapeutic insights from the present genetic 
discoveries. Finally, the genetic findings support shared biological etiology for 
different psychiatric disorders, and challenges the current categorized clinical view.  
 
Due to the technical advances, the field of genetic research has evolved rapidly from 
genotyping several tens or hundreds of genetic markers to genotyping millions of 
them simultaneously. Practically all common variation in the human genome can be 
interrogated efficiently in one GWAS experiment. Population level sequence data 
obtained from large sequencing studies, such as 1000 genomes (Durbin et al. 2011) 
and UK10K (http://www.uk10k.org/), both of which also include Finnish samples, 
can be used to impute the SNP array data to include also rare sequence variants. 
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Here the unique population history and reduced genetic diversity of Finns can be of 
great scientific value. Thousands of individuals from the Finnish population cohorts 
have GWAS data available and a large reference sequence data, gathered from 
different research projects, collectively called the Sequencing Intiative Suomi (SISu-
project) is already available (http://www.nationalbiobanks.fi/ , http://sisu.fimm.fi/). 
The current trend in genetics has moved beyond GWAS to high coverage exome and 
whole genome sequencing of even larger sample sets. The accumulation of genetic 
data in the future will provide grounds for systematically addressing the impact of 
especially rare variants in various phenotypes including those related to severe 
mental disorders. For studies of common variants, special populations have provided 
limited benefit, but for rare variants this is likely to change. 
 
Genetics has opened up new avenues in studies of mental health that allows the 
postulation of novel hypotheses about the biological pathophysiology of severe 
mental disorders, which has previously been largely unattained. Yet genetics alone 
is insufficient but rather it contributes another stream of convergent evidence to 
merge with those of from multiple disciplines, including molecular biology and 
neuroscience, which will be crucial in illuminating the biological mechanism 
leading to these disorders.  
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